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LOSS OF THE PROTECTIVE ARM OF RENIN-ANGIOTENSIN-SYSTEM 
RESULTS IN HEMATOPOIETIC STEM/PROGENITOR CELL DEFECTS, GUT 
DYSBIOSIS AND RETINOPATHY IN DIABETES 
 
Angiotensin-converting enzyme 2 (ACE2) is the primary enzyme of the 
vasoprotective axis of the renin-angiotensin system (RAS). We tested the 
hypothesis that the protective arm of the RAS axis can i) act to maintain 
homeostasis in the diabetic bone marrow stem cell compartment, ii) regulate the 
reparative function of the hematopoietic stem/progenitor cells (HSPCs) and iii) 
modulate the gut microbiota composition. All processes could influence the 
development of diabetic retinopathy.  
 
Diabetic ACE2 knockout (KO)/C57BL/6-Ins2WT/C96Y (Akita) mice were examined at 
3 and 9 months after the onset of diabetes and compared to age-matched controls. 
Both ACE2KO-Akita and Akita cohorts showed reduced retinal thickness by optical 
coherence tomography at 9 months of diabetes. The absence of ACE2 in 9-month 
diabetic mice led to an accelerated increase in acellular capillaries, a hallmark 
feature of diabetic retinopathy. The absence of ACE2 also caused a reduction of 
both long-term and short-term repopulating HSPCs in the diabetic bone marrow at 
9 months of diabetes. Reparative function studies showed that ACE2KO 
exacerbated diabetes-induced impairment of lineage-c-kit+ HSPC migration and 
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proliferation as early as 3-month of diabetes. HSPCs from both early and late stage 
diabetic mice, pretreated with Ang-(1-7) or alamandine (two downstream peptides 
of ACE2) showed restored migration and proliferation. The gut microbiota has 
been implicated in the pathogenesis of diabetes. Analysis of the gut microbiome 
also revealed a distinct bacterial profile in ACE2KO-Akita group, with a great 
diversity of bacterial types that were previously reported to contribute to diabetic 
pathogenesis, including Tenericutes at the phylum level and Mollicutes at the class 
level, and with an activation of peptidoglycan biosynthesis pathways. Flow 
cytometry analysis showed that loss of ACE2 led to less infiltration of circulating 
angiogenic cells in the gut which may lead to an increased endothelial cell 
permeability in the intestinal endothelium. This leakage into the blood may promote 
systemic inflammation known to contribute to the pathogenesis of diabetic 
retinopathy. These data suggested a loss of the protective arm of RAS contributes 
to the impairment of HSPCs and alteration of gut microbiota, both of which may 
contribute to the development of diabetic retinopathy. 
 
Maria B. Grant, MD, co-chair  
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Chapter 1: Introduction - RAS balance within bone marrow-gut-retina axis: 
implications for diabetic retinopathy therapeutics 
 
Renin- angiotensin system  
 
The renin-angiotensin system (RAS) is known as a key regulator of blood pressure 
and electrolyte balance. There are two main axes composed of eight central 
components (Figure 1-1): the classic deleterious RAS (angiotensin I converting 
enzyme (ACE)/ Angiotensin II (Ang II)/ Ang II type 1 receptor (AT1R)) and the 
protective RAS (ACE2/ Angiotensin-(1-7) (Ang-(1-7))/ alamandine/ MAS/ Mas-
related G protein coupled receptor, membrane D (MRGPRD) [1, 2]. Before the 
discovery of the protective RAS axis, most of the studies focused on the classic 
RAS which was found to have deleterious effects on the cardiovascular system, 
including inducing vasoconstriction, fibrosis and inflammation. Moreover, ACE2 
inhibitors and AT1R blockers have been used in clinic practice to successfully 
treated patients with cardiovascular diseases. In the past two decades, a novel 
RAS axis was found that can counteract the most detrimental effects caused by 
the classic RAS axis.  The “beneficial” axis is composed of ACE2 which can 
convert deleterious Ang II into beneficial Ang-(1-7) and, thus, this arm of the RAS 
is considered to play a protective role in maintaining RAS homeostasis [3]. In the 
last 4 years, another novel peptide, alamandine, was also discovered that can be 
produced by ACE2 and can have beneficial effects on the cardiovascular system 
[4]. 
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As a major vasoactive peptide in the canonical RAS, Ang II binds two different cell 
surface receptors, AT1R and AT2R, which both belong to the G-protein coupled 
receptor family [5, 6]. AT1R, which is abundantly expressed in the cardiovascular 
system, is responsible for the major physiological and pathological effects of AngII 
[7]. The activation of AT1R induces intracellular effects through multiple signaling 
pathways, primarily adenylyl cyclase / mitogen-activated protein kinase (MAPK)/ 
phospholipase C (PLC)/phospholipase A2(PLA2)/ Janus kinase (JAK) pathway, 
PLC/inositol trisphosphate (IP3) pathway, signal transducers and activators of 
transcription (STAT) pathway and activation of nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase [8]. In contrast, AT2R is not as widely expressed as 
AT1R and its expression is typically regulated in a tissue-specific manner [6, 9]. 
Activation of AT2R mainly induces the nitric oxide (NO)/ cyclic guanosine 
monophosphate (cGMP) pathways through bradykinin or through activation of 
endothelial nitric oxide synthetase (NOS) [10], which counteracts the effects of 
AT1R and reduces inflammation, apoptosis and cardiac remodeling.  
 
In the noncanonical RAS, two key vasoactive components are Ang-(1-7) and 
alamandine. Ang-(1-7) is mainly produced by converting Ang II by ACE2, and 
alternatively thought converting Ang I by neutral endopeptidase (NEP) [11, 12]. 
The receptor for Ang-(1-7) is MAS, a G protein coupled receptor. The binding of 
Ang-(1-7) to MAS activates the MAPK pathway, phosphoinositide 3-
kinase(PI3K)/Akt pathway and NADPH oxidase, and eventually leads to the 
activation of several downstream effectors, such as vasodilator NO, forkhead box 
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protein O1 (FOXO1) and cyclooxygenase-2 (COX-2). MAS activation promotes 
vasodilation, reduces inflammation, reduces oxidative stress, and improves 
glucose uptake and lipolysis [13-15]. Another vasoactive peptide, alamandine, is 
generated either from Ang A by the catalytic function of ACE2 or from Ang-(1-7) 
by a decarboxylation reaction [4]. Alamandine has similar beneficial effects to Ang-
(1-7) and promotes vasodilation and reduces fibrosis, however alamandine signals 
through a different receptor, MRGPRD [2, 16].  
 
Hematopoietic stem/progenitor cells (HSPCs) and diabetes 
 
Bone marrow-derived HSPCs are essential for maintaining hematopoietic 
homeostasis by self-renewal and differentiation into different lineages. Growing 
evidence also suggests the important role of HSPCs in angiogenesis and vascular 
repair. In 1997, Asahara et. al. isolated cluster of differentiation (CD) 34+ cells from 
the peripheral blood and considered these cells as “endothelial progenitor cells” or 
EPCs [17]. Another better defined population, CD34+KDR+CD133+ cells, were 
thought to be EPCs and able to form endothelial cells. However, most recent 
studies support that CD34+KDR+CD133+ cells are hematopoietic cells that express 
CD45 and are not EPCs,  nor do these cells have true vessel forming activity [18, 
19].  Another population of cells that are true “EPCs” and have vessel forming 
activities are CD34+CD45- cells, called endothelial colony forming cells (ECFCs) 
[18, 19]. Both CD34+KDR+CD133+CD45+ cells and CD34+CD45- cells have been 
shown to contribute to vascular repair. While ECFCs promote healing by directly 
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integrating into injured vessels and forming functional vessels in vivo [20-22], 
HSPCs promote vascular homeostasis by providing paracrine factors to injured 
vessels [23-26].  
 
A previous study by Schatteman et. al. showed that local injections of CD34+ cell 
accelerate the restoration of blood flow in diabetic mice with hindlimb ischemia [27]. 
Ramos et. al. further demonstrated that the injection CD34+CD45+CD133+CD38+ 
cells isolated from cord blood improved reperfusion in a hindlimb ischemia model; 
however, the cells maintained their hematopoietic properties and did not 
incorporate into blood vessels [28]. Human CD34+ cells release multiple growth 
factors and cytokines [29]. Studies showed that HSPCs modulated CD14+ cell 
differentiation and accelerate vascular network formation by releasing paracrine 
factors, such as interleukin (IL)-8, hepatocyte growth factor (HGF) and monocyte 
chemoattractant protein-1 (MCP-1) [30-32]. Because of the important roles in 
vascular repair, HSPCs have become a novel target of autologous cell therapy for 
diabetes-induced vascular complications, including diabetic retinopathy. However, 
because HSPCs from diabetic individuals are typically dysfunctional, it is critically 
important to understand the underlying mechanisms of this impairment before 
these cells are used for autologous cell therapy.  
 
There is reduced egress of diabetic HSPCs from the bone marrow after injury and 
decreased vasculogenic potential of these cells in rodent models of type 1 and 2 
diabetes [33-35]. Moreover, clinical studies also demonstrated that diabetes 
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results in a comprehensive remodeling of the bone marrow microenvironment, 
including a reduction of hematopoietic cells, an increase in fat deposition, and 
microvascular rarefaction [36]. Poorly controlled glucose levels can cause defects 
of HSPCs and also alter the microenvironment surrounding the cells [33, 37-40]. 
Although satisfactory glycemic control helps to restore the number of circulating 
progenitor cells when compared to those with poor glycemic control, the number 
is still lower compared to healthy subjects, suggesting other risk factors and 
mechanisms may also participate in maintaining bone marrow homeostasis in 
diabetes [41].  
 
The molecular pathways involved in the HSPC dysfunctions include accumulation 
of reactive oxygen species (ROS), destabilization of hypoxia inducible factor-1 
(HIF-1) and inflammation. Sustained exposure of endothelial cells and other cell 
types to high glucose leads to over-production of ROS, which further activates 
multiple pathways, including increased advanced glycation end products (AGEs), 
activation of protein kinase C (PKC) pathways, and increased glucose flux via 
aldose-reductase pathway, all of which can be blocked by reduction of ROS [42, 
43]. In health, the bone marrow niche is well-characterized by the presence of 
active antioxidant defense systems to maintain ROS at a low level. While a modest 
generation of ROS promotes stem cell self-renewal and differentiation, and 
migration to the injured area to help vascular repair [44, 45],  diabetes results in a 
sustained increase in ROS. This results in a sustained  inflammatory environment, 
accumulation of AGEs, and alterations in epigenetic modifications of key genes, 
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eventually resulting in stem cell senescence, reduced response to hypoxia and 
decreased angiogenic potential [46-49].  
 
Hypoxia induces activation and stabilization of HIF-1, a transcription factor for a 
cascade of genes, including stromal cell-derived factor-1 alpha (CXCL12) and 
vascular endothelial growth factor (VEGF) [39, 50-52]. CXCL12 is important for 
recruiting HSPCs to the region of damaged vasculature. In diabetes, the 
accumulation of ROS and toxic glycolytic metabolites impairs the stabilization and 
activation of HIF-1, therefore leads to impaired homing and deficiencies in 
angiogenic potential [52-54]. Inflammation is also considered as a key regulator of 
HSPC fate in diabetes. Under homeostatic conditions, basal niche and immune 
signaling mediate a balanced lineage output with precise control of the production 
of myeloid and lymphoid cells. However, in diabetes, the increased 
proinflammatory signaling, including Toll-like receptors (TLRs), interferons (IFNs), 
tumor necrosis factor (TNF), and IL-1, adversely impact the long-term repopulating 
(LT)-HSCs by increasing their apoptosis and results in overproduction of myeloid 
lineages. Alternatively, lymphoid output (immunosenescence) and erythroid 
production (anemia) are often diminished [55-62].  
 
RAS within bone marrow hematopoietic stem/ progenitor cells 
 
Even though systemic RAS plays an important role in the homeostasis of the 
cardiovascular system and electrolyte balance, RAS components are also 
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reported to present in many other tissues including bone marrow. The notion of 
RAS involved in the hematopoietic system was identified after ACE inhibitors 
became widely used in clinics. Two research groups both reported that high dose 
of ACE inhibitors resulted in anemia and leukopenia [63, 64].  Major components 
of the RAS were identified in bone marrow cells: HSPCs, stromal cells and 
mesenchymal stem cells (MSCs) [65]. The findings of a “local RAS” in various 
tissues have changed the perspective of using RAS as a therapeutic target beyond 
the cardiovascular system.  
 
The RAS axis affects multiple aspects of hematopoiesis, including erythropoiesis, 
white blood cells formation as well as the angiogenic potential of HSPCs. Ang 
II/AT1R has been reported to stimulate and increase early erythroid progenitors 
[66, 67]. An increased hematocrit was observed in AT1R transgenic mice, while a 
reduction of hematocrit was found in AT1R knockout mice [68, 69].  Studies 
suggested that the pro-erythropoiesis effect of the classic RAS may be through 
JAK/STAT pathway activation that increases the level and activity of erythropoietin 
(EPO) [70-73]. Interestingly, Ang-(1-7) in the protective RAS also enhances 
erythropoiesis and reduces anemia in cancer patients following the toxic effects of  
chemotherapy [74, 75]. 
 
Because treatment with ACE inhibitors leads to leukopenia in clinic subjects, the 
classic RAS is believed involved in the formation of white blood cells [64]. ACE2 
depletion results in impairment in normal myelopoiesis [76]. Under physiological 
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conditions, ACE knockout mice exhibit a decrease in neutrophils, but normal levels 
of monocytes and macrophages [76-78]. Moreover, under hematopoietic stress, 
such as irradiation or chemotherapy, Ang II infusion restores the numbers of white 
blood cells [77]. Ang II mainly plays a facilitating role in myelopoiesis as Ang II 
increases the colony forming unit (CFU)-granulocyte, monocyte and CFU- 
granulocyte, erythrocyte, monocyte, megakaryocyte but only in the presence of 
colony-stimulation factors [79].  
 
Besides myelopoiesis, the classic RAS also plays a role in lymphoid development. 
AT1R promotes the proinflammatory responses of lymphocytes. Moreover, 
infusion of Ang II results in an imbalance of CD4+ T-cells (T helper) with reduced 
Th2 and increased Th1, leading to increased generation of pro-inflammatory 
cytokines [80]. Accordingly, the classic RAS contributes to the systemic 
inflammation at least partly through modulation of hematopoiesis. In addition, Ang 
II recruits monocyte to the vascular wall and activate these cells to secret pro-
inflammatory cytokines. Ang II can also increase ROS production and activate NF-
kB signaling pathways contributing to an inflammatory phenotype in tissue 
samples [81, 82].   
 
Studies have reported that in the classic RAS, Ang II/AT1R signaling promotes 
HSPC recruitment and results in a pro-angiogenic effect as part of an acute 
response. In contrast, in chronic conditions such as diabetes, it leads to inhibition 
of HSPC proliferation and functions [83-86]. One mechanism involved in this effect 
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is activation of NAPDH oxidase activity followed by initiation of JNK/ p38 MAPK/ 
Bax/ Bcl2 apoptosis pathways [87]. In addition, ROS-mediated cellular 
senescence may also participate in AT1R-induced deleterious effects on HSPCs 
[88, 89].  
 
One major effect of Ang-(1-7) on hematopoiesis is improving proliferation and 
migration functions of HSPCs in response to different stress, such as 
chemotherapy, irradiation and diabetes [74, 75, 90, 91]. In mononuclear cell 
cultures from rat or mouse bone marrow, Ang-(1-7) treatment was able to increase 
the number of angiogenic cells with VEGFR2 expression [92]. Although some of 
the effects of the protective RAS may due to reduced NADPH oxidase and 
increased eNOS [93], the molecular mechanisms of Ang-(1-7)/MAS signaling 
remain largely unknown. 
 
Gut microbiota and diabetes 
 
The gut microbiota is a dynamic ecosystem. Both the environment factors and host 
conditions can affect its composition at the phylum and class levels, which further 
influences the gut and other distant organs [94]. Gut microbiota contributes to a 
large array of human diseases, including obesity and diabetes [95, 96]. An altered 
composition of the microbiota has been showed in both type 1 (T1D) and type 2 
diabetic (T2D) individuals. By studying the gut microbiome from young children 
that are at high genetic risk for type 1 diabetes and from age-matched healthy 
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subjects, Adriana et. al. showed clear differences in the microbiota between these 
two cohorts [97]. Firstly, the microbial diversity was reduced over time in the 
autoimmune subjects. In addition, there was an increase in Bacteroidetes level and 
a decrease in Firmicutes level in autoimmune children, suggesting that low ratio of 
Firmicutes to Bacteroidetes may be used as a biomarker for development of T1D. 
Another case-control study in children with T1D [98] observed reduced Firmicutes 
and increased Bacteroidetes levels. Therefore, the ratio of Firmicutes to 
Bacteroidetes is reduced in T1D and negatively correlates with plasma glucose 
levels. Interestingly, this study also demonstrated that increased levels of 
Clostridium are positively correlated with hemoglobin A1c (HbA1c) levels.  
 
Consistent with the T1D studies, Larsen et. al. also reported reduced Firmicutes 
level in T2D, and the ratio of Firmicutes to Bacteroidetes negatively correlated with 
glucose concentrations in plasma [99]. In a cohort of Chinese type 2 diabetic 
patients, a reduction in butyrate-producing bacteria and an increase in several 
opportunistic pathogens was observed [100]. In another two independent studies 
of T2D subjects, the abundance of Clostridium species was decreased in diabetic 
subjects, and the level was negatively correlated with HbA1c and fasting glucose 
levels [101, 102]. This is contradictory with findings in T1D subjects.  
 
Despite the discrepancies of the results from different groups, all the studies 
observed clear gut microbial dysbiosis in diabetes when compared to healthy 
controls. Therefore, it is critical to understand the underlying mechanisms through 
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which the gut microbiota contributes to the development of diabetes and its 
complications. Chronic low-grade systemic inflammation has been suggested to 
contribute to the pathogenesis of diabetes and its vascular complications. Bacteria-
derived metabolic endotoxemia, including peptidoglycan (PGN) and 
lipopolysaccharide (LPS), are both considered as triggers for chronic inflammation 
[103-106]. The endotoxin, LPS, was associated with both prevalent and incident 
diabetes [107]. Patrice et. al. demonstrated in an animal model that high fat diet 
chronically increased the proportion of LPS-containing bacteria in the gut and 
plasma LPS levels. Moreover, continuous subcutaneous infusion of LPS for 4 
weeks caused hyperglycemia, hyperinsulinemia and adipose tissue weight gain to 
a similar level as in mice with high fat diet [103]. Besides LPS, another endotoxin 
PGN was also found to promote diet-induced insulin resistance and inflammation 
[106]. LPS initiates inflammatory effects through toll like receptor (TLR)-2/4 
activation [108-110]. PGN causes proinflammatory responses mainly via activation 
of nucleotide oligomerization domain 1 (NOD1) protein in adipocyte and 
hepatocyte [111, 112]. Unlike NOD1 that mediates PGN-induced inflammation, the 
intact NOD2 and PGN sensing are important for stabilizing microbiota and 
preventing bacterial translocation from the gut to liver and adipose tissue [106].  
 
Increased gut permeability in diabetes also provides an opportunity for the 
bacterial antigens and microbiota to affect the systemic metabolism [113, 114]. 
The disruption of gut epithelial and vascular barriers lead to increased release of 
bacterial antigen and result in an increase in systemic inflammatory cytokines [115]. 
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Recent studies suggested an interaction between gut microbiota and immune 
system in diabetes. Frederico et. al. showed that gut microbiota released antigens 
that drove the differentiation of T helper 1 (Th1) and Th7 cells in pancreatic lymph 
nodes and contributed to the onset of T1D [116]. Several studies demonstrated 
that using one or a combination of antibiotics alters the microbiota composition, 
thereby leading to a modulation of immune system in a T1D mouse model [117-
119]. Even in type 2 diabetes, chronic obesity induced-inflammation and beta cell 
stress can activate the immune system, which further induces NOD and TLR 
pathways to produce cytokines that destroy beta cells [120-122].  
 
The gut microbiota is able to modulate energy metabolism. The gut microbiota 
utilizes two sources of nutrients, dietary components and host-derived 
components, like shed epithelial cells and mucus. During utilization, the microbiota 
generates several metabolites, such as short-chain fatty acids (SCFA) through 
carbohydrate fermentation and phenolic metabolites through protein fermentation 
[123]. Needell et. al. reported that maternal treatment with SCFA modulated 
immunity and ameliorated T1D in offspring [124]. Canfora et. al. demonstrated that 
colonic administration of SCFA mixtures increased fasting fat oxidation and energy 






Role of RAS in gut microbiota 
 
RAS has been shown to play an important role in the gastrointestinal (GI) tract. 
Even five decades ago, it was suggested that Ang II regulates the contraction of 
the gut smooth muscle by a direct effect or by activation of the myenteric plexus 
cholinergic neurons [126-128]. Most of the components of RAS axis have been  
identified in the GI tract [129]. In the small intestine, ACE is located abundantly in 
epithelial cell brush border and in the endothelium of mesenteric microvasculature 
[130]. ACE2 is present in abundance in brush borders of epithelial cells, muscularis 
propria and mucosa, as well as, in the mesenteric microvascular endothelium and 
smooth muscle cells [131]. Remarkably, the GI system, especially ileum, 
duodenum and jejunum, is reported to have the highest ACE2 mRNA expression 
levels among 72 human tissue types examined [132].  
 
AT1R is located in epithelial brush order, the myenteric plexus, endothelium in the 
muscularis propria and muscle layers, while AT2R is mainly expressed in the 
myenteric plexus [133-136]. Ang I and Ang II have been reported to present in the 
bottom part of crypts [137]. Angiotensinogen is also widely expressed in multiple 
locations in the rat small intestines, including epithelial brush border, lamina 
propria, submucosal blood vessels and muscularis mucosa propria [138]. In the 
colon, the localization of RAS components is different from the small intestine [129]. 
ACE is mainly expressed in mesenteric microvasculature, mesenchymal cells as 
well as lamina propria, and only weakly presents in the epithelial layer in the colon. 
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ACE2 is localized to the endothelium of the mesenteric microvasculature in the 
colon and is not expressed in the epithelial layer [131, 139]. Both AT1R and AT2R 
are detected on surface of epithelium and in crypt bases in the colon. AT1R is also 
expressed in macrophages, mucosal vessel walls and myofibrolasts [139]. 
 
RAS affects multiple pathophysiological functions in the gut. ACE inhibitor or 
depletion affects epithelial cell apoptosis and turnover [140, 141]. Low doses of 
Ang II and Ang III stimulate water and sodium absorption in the jejunum possibly 
via conjugation with sympathetic neuron system. In contrast, high doses of Ang II 
inhibit water and sodium absorption [142-145]. Ang II also promotes cholesterol 
absorption through up-regulation of Niemann-Pick C1-like 1 protein expression 
[146]. In addition, Ang II reduces the expression of sodium-dependent glucose 
transporter, therefore inhibiting glucose transport across the bush border 
membrane in the jejunum [138]. Both ACE and ACE2 on brush borders serve as 
peptidases that regulate mucosal digestion and peptide and amino acid absorption 
[147-149]. Ang II mediates alkaline secretion through AT2R in the duodenal 
mucosa [150]. 
 
In a mouse model of colitis, both Ang II and AT1R levels are elevated [151]. ACE 
inhibitors and ARB treatment decrease TGF- α, TGF- β expression and reduce 
inflammation in colitis [151-155]. Angiotensinogen deficiency also prevent 
inflammation and development of colitis [156]. 
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Studies in the last several years have highlighted the role of RAS in gut function 
and microbiota composition. Studies by our group and others showed ACE2 is 
highly abundant in both mouse and human small intestine, but expressed at a low 
level in the colon  [132, 157, 158]. In 2001, a protein named “collectrin” was 
discovered in the kidney and interestingly, its sequence was highly homologous to 
the ACE2 c-terminus [157]. Studies uncovered the role of collectrin as a key 
subunit for the solute carrier 6 (Slc6) family of neutral amino acid transporters 
(B0AT1) and B0AT3, the Slc1 glutamate and aspartate transporter EAAT3, and the 
amino transporter, signaling threshold regulating transmembrane adaptor 1 (SIT1) 
in the kidney [159, 160]. Interestingly, collectrin is not seen in the gut, but B0AT1 
is observed. ACE2, that shares a similar structure with collectrin, plays an identical 
role as collectrin in gut biology [161, 162]. ACE2 binds and interacts with the 
neutral amino acid transporter, B0AT1 in the small intestine, which promotes the 
absorption of nutrients [149, 162]. ACE2 colocalizes with B0AT1 on enterocytes of 
the small intestine but does so with noncatalytic effects. Using an ACE2 knockout 
model, Tatsuo et. al. demonstrated loss of ACE2 resulted in a dramatically reduced 
plasma tryptophan level. The imbalance of amino acids homeostasis occurred 
through downregulation of B0AT1 expression level and led to increased 
susceptibility to colitis and an altered gut microbiota [161]. Moreover, they also 
verified that ACE2-induced malnutrition is independent of Ang II and apelin 
cleavage. The mechanisms by which the ACE2/ B0AT1 interaction affects 
microbiota are still unclear; however, one explanation is that ACE2 deficiency-
mediates a reduction of tryptophan levels and reduces mTOR pathway activation. 
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Low mTOR activation leads to reduced antimicrobial peptide secretion by Paneth 
cells which alter microbial composition [158]. The ACE2 in the small intestine can 
also stabilize another amino acid transporter, SIT1, that regulates sarcosine, 
proline, and betaine transfer[160, 163]. It is still largely unknown whether ACE2 
contributes to the change of microbiota seen in diabetes and in diabetic 
complications. The functions of ACE2 in gut biology and the microbiota and the 
complicated communication between the microbiota and host factors need further 




Diabetic retinopathy (DR) is the leading cause of blindness in working age adults 
in the US [164]. The most common classification for DR is based on a number of 
photographically detectable features as indicators of disease progression [165-
167]. DR is classified into two main forms: non-proliferative diabetic retinopathy 
(NPDR) and proliferative diabetic retinopathy (PDR). NPDR is further classified 
into mild, moderate and severe NPDR based on the features, such as 
microaneurysms, intraretinal hemorrhages, venous beading and other intraretinal 
microvascular abnormities. PDR is characterized by ocular neovascularization and 
vitreous/preretinal hemorrhage. The newly formed vessels in PDR stage are often 
very fragile and leaky. The fibrous connective tissues adherent to and grown 
around the vessel and the resultant traction finally cause hemorrhage and/or retinal 
detachment. Both diabetes duration and poor glycemic control contribute to the 
 17 
development of DR [168-170]. Dyslipidemia is considered another risk factor for 
DR, which is supported by both the Fenofibrate Intervention and Event Lowering 
in Diabetes (FIELD) and the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) studies [171, 172]. In these clinical trials, fenofibrate and simvastatin, 
used for lipid control helped ameliorate the progression of DR. Blood pressure 
control is also important for the development of DR [168, 173]. The United 
Kingdom Prospective Diabetes Study (UKPDS) group demonstrated that tighter 
blood pressure control (<150/85 mmHg) significantly reduced the development of 
microaneurysms, hard exudates and cotton wood signs in the retina, compared to 
loose blood pressure control (<180/105 mmHg) [174]. The Hoorn study 
demonstrated that diabetic patients with hypertension had two times higher risk of 
developing retinopathy after 10 years than diabetic individuals without 
hypertension [175]. 
 
Vascular degeneration is considered an essential feature in the pathogenesis of 
DR, which directly results in non-perfusion and hypoxia in the injured retina. One 
early histopathological change observed is thickening of the basement membrane 
of retinal capillaries. This is observed in both diabetic individuals and animal 
models. Basement membrane thickening is due to increased extracellular matrix 
modifications, such as collagen IV, laminin and fibronectin [176-180].  
 
Pericytes are considered a primary target during the early stage of DR [181]. 
Endothelial cells are also dysfunctional at a very early stage, although they have 
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adaptive responses and compensation for a period of time, but eventually 
endothelial cells become dysfunctional [182, 183]. All the alterations, including 
pericyte and endothelial cell loss and thickening of basement membranes, lead to 
a central pathological hallmark of DR, acellular capillaries. Acellular capillaries are 
defined as basal membrane tubes with no nuclei following the procedure of trypsin 
digestion of the retina. Microaneurysms are another “hallmark” lesion associated 
with DR and are easily observed on color fundus photography.  Microaneurysms 
represent regions of saccular vascular weakness that are associated with vascular 
leakage. Clinical pathological studies have shown that non-perfused retina 
capillaries are often “downstream” of microaneurysms that often occur on the 
arteriolar side of the microvasculature [176, 184].  This “hallmark” lesion may 
become infiltrated with monocyte and polymorphonuclear cells [185]. However, it 
does not occur in rodent models of diabetes, thus limiting research on the 
pathogenesis of this particular lesion.  
 
Besides vascular degeneration, dysfunction of neural retina is also seen in DR 
[186]. Neural retinal changes include i) apoptosis and dysfunction of 
photoreceptors which corresponds to abnormalities of the cone and rod signals on 
electroretinograms, ii) apoptosis of ganglion cells, and iii) dopaminergic and 
cholinergic amacrine cell loss [187-191]. Retinal glial cells also play an important 
role in communication between the blood vasculature and neurons [192, 193]. 
There are 3 types of glial cells in the retina: two macroglial cell types (astrocytes 
and Müller cells) and microglial cells. In particular, Müller cells are the structural 
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and functional link between vasculature and neurons. They process waste 
products and nutrients and help to maintain the function of both the neurons and 
blood vessels [193]. In diabetes, an increase in the expression of the glial fibrillary 
acidic protein (GFAP) is observed. Synthesis of glutamate also occurs in Müller 
cells of diabetics and eventually leads to excitotoxicity, impaired blood-retina 
barrier and neuron loss [194-196].  
 
The key cell signaling pathways involved in microvascular complications include 
increased oxidative stress, inflammation, accumulation of AGEs, activation of PKC 
and polyol pathway flux [42]. It is worth noting that these cell signaling pathways 
do not work independently, but work in concert to promote the development of DR.  
These signaling pathways and their metabolites not only cause the apoptosis of 
retinal cells and overproduce of the extracellular matrix, but also make the 
microenvironment unfavorable for vascular repair [197, 198].  
 
Bone marrow derived progenitor cells have been suggested to play an essential 
role in vascular repair. However, diabetes and poor glycemic control results in low 
circulating levels of the progenitor cells and cells with impaired vasoreparative 
potential [199-204]. The impairment in the retinal vasculature and the lack of 
reparative angiogenesis together contribute to the progression of DR.  
 
Overexpression of VEGF in the ocular fluid of diabetic subjects has been closely 
related to the development of neovascularization [205]. More recently, a role of 
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semaphorins in regulation of pathogenic angiogenesis has also been 
demonstrated [206]. Semaphoring 3A, a protein involved in axonal growth cone 
guidance, is secreted by retinal neurons in response to hypoxia and is able to guide 
the neovessel growth toward the vitreous while suppressing the revascularization 
response in the ischemic retina causing neovascularization.  
 
Current treatment options for DR are still very limited. The control of systemic risk 
factors, like hyperglycemia, dyslipidemia, blood pressure and smoking will slow the 
progression of DR. Intravitreal anti-VEGF drugs, laser photocoagulation, 
corticosteroid agents and vitreoretinal surgery are the current therapies to reduce 
sight-threatening diabetic macular edema or PDR [197]. Current therapeutic 
strategies mainly focus on treatment of advanced retinopathy and there is no 
effective treatment to stop or slow the progression at early stages, beyond treating 
systemic risk factors.  
 
Role of RAS in diabetic retinopathy 
 
Both mouse and human eyes have their own tissue-specific RAS, which is 
independent of, and can have interactions with, system RAS [207-210]. Local RAS 
can be divided into two groups based on whether it depends on the circulating RAS 
for biosynthesis of the local RAS peptides [211]. Studies have shown that Ang II 
level is increased in the vitreous fluid of patients with advanced PDR, and 
promotes neovascularization by potentiating vascular endothelial growth factor-
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mediated pathologically angiogenesis [212-214]. However, no studies have 
examined the levels of Ang-(1-7) at the PDR stage. Unlike human subjects, 
diabetic mouse models without genetic modifications do not develop PDR, but only 
reach the non-proliferative stage.  
 
An imbalance of ACE/ACE2 with a reduction of protective RAS was found in the 
retina from STZ-induced diabetic mice[215, 216]. Administration of ACE2 and Ang-
(1-7) in the retina prevents or reverses DR in a T1D model [215]. ACE2 activation 
also protects retinal ganglion cells in diabetic rats [217]. Interestingly, RAS within 
HSPCs also plays an essential role in the development of DR. The protective RAS 
in HSPCs is important for maintaining vasoreparative functions in response to 
vascular injury [93].  
 
Bone marrow-retina connections 
 
The bone marrow serves as a pool for both HSPCs with angiogenic properties and 
for monocytes with proinflammatory features. The bone marrow has an influence 
on many other organs in diabetes, including kidney, brain and retina [218, 219]. 
Diabetes impairs the bone marrow architecture, function, and the number of 
reparative cells. Diabetes also impacts bone marrow-derived immune cells. 
Typical characteristics of the diabetic bone marrow include neuropathy, 
microangiopathy, stem cell depletion, and an alteration in fat deposition, along with 
a shift of hematopoiesis [37].  
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Efficient release of bone marrow-derived circulating angiogenic cells into the 
circulation and mobilization of these cells into injured tissues is a critical 
component of vaso-reparative and protective mechanisms that occur in response 
to vascular ischemia and/or damage. Studies suggest that diabetes-induced bone 
marrow neuropathy results in trapping of stem/progenitor cells in the bone marrow 
and decreased the release of these cells into the circulation.  Bone marrow 
neuropathy precedes the development of  diabetic retinopathy [220, 221].  
 
One mechanism for HSPC dysfunction is the defective HIF-1α/VEGF/CXCL12 
signaling pathway [222]. DPP-4, an enzyme that regulates the concentration of 
CXCL12 may also contribute to diabetes-induced HSPC mobilopathy. Our group 
showed that CD34+ cells isolated from diabetics showed impaired migration toward 
CXCL12 and reduced proliferation, contributing to reduced vascular repair 
potential. Local injection of adeno-associated virus that over express Ang1-7 
restored HSPC migratory function,  improve  localization to areas of injury and help  
the repair of injured retinal vasculature by secreting paracrine factors [93]. 
 
Hyperglycemia results in an imbalance of hematopoiesis and shifts the fate of 
progenitor cells towards their differentiation to more inflammotory cells and 
reduces their differentiation to progenitors with angiogenic potential [219]. Just like 
HSPC dysfunction, the imbalance of myelopoiesis also plays an essential role in 
the pathological changes of DR [223, 224]. Diabetes disturbs the distribution and 
balance of M1 (inflammatory) and M2 (anti-inflammatory) macrophages in the 
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bone marrow and blood, and affects their response to G-CSF stimulation [218]. 
Studies showed that diabetes induce accumulation of bone marrow-derived 
monocytes in the retina and  pro-inflammatory myeloid cells from bone marrow 
play a critical  role in endothelial cell loss and vascular degeneration in diabetic 
retina [223, 225]. Harshini et. al. tracked the bone marrow cells by using a STZ-
induced DR model with green fluorescent protein (GFP)-labeled bone marrow 
transplantation, and demonstrated that diabetes significantly increased the 
filtration and activation of GFP-expressing microglial in the retina while reducing 
the number of bone marrow-derived circulating angiogenic cells [221]. Prabhakara 
et. al. showed that hyperglycemia increases the production of damage associated 
molecular patterns, S100A8/S100A9, in neutrophils. Neutrophil S100A8/S100A9 
further interacts with receptors for AGE on common myeloid progenitor cells and 
results in increased myelopoiesis [226]. Interestingly, local administration of ACE2 
in the retina reduced diabetes-mediated monocyte infiltration and reverses 
retinopathy in animal models [215].  
 
Bone marrow-gut crosstalk 
 
The concept of communication between the gut and the bone marrow is supported 
by evidence that the gut microbiota is an extrinsic regulator of hematopoiesis [227]. 
Very low levels of microbial antigens set the size of the bone marrow myeloid cell 
pool which correlates strongly with the complexity of intestinal microbiota [228]. As 
mentioned before, TLRs, especially TLR-4, are receptors that are essential for 
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mediating microbial antigens, such as LPS, related functions. Interestingly, TLR-4 
is highly expressed in bone marrow-derived cells, including macrophages, 
providing the possibility that bone marrow-derived cells can be regulated by 
microbial antigens. Maziyar et. al. established a mouse chimera model with 
hematopoietic cell-specific depletion of TLR-1 (BMT-TLR-4−/−). Although BMT-
TLR-4−/− mice fed a high fat diet did develop obesity similar to wild time mice, they 
did not have fasting hyperinsulinemia and were protected from insulin resistance. 
This study suggested that microbial antigen-mediated modulation of bone marrow 
macrophage content can contribute to the systemic inflammation and insulin 
resistance [229].  
 
The microbiota is   reported to modulate the proportion and function of HSPCs. In 
a Rag1-/- mouse model lacking all mature lymphocytes, there is an alteration of 
microbiota composition, which further results in a dramatic reduction of LSK, LT-
HSC and short term repopulating (ST)-HSC numbers and proportion, and leads to 
an increase in myeloid progenitors. Rag1-/- mice received fecal transplantation 
using feces from control mice and show a restoration of HSPC levels in bone 
marrow [230]. The microbiota of obese mice also alters the number and 
reconstitution ability of long term HSCs and shifts the hematopoiesis from 




The gut microbiota plays an essential role in modulating immune responses. There 
are many  immune cells, including dendritic cells, lymphocytes and macrophages, 
in the gut lamina propria, most of which are derived from bone marrow [232]. 
Commensal gut microbiota regulates proper immune function possibly through 
microbial antigens, which sustain steady-state recruitment of neutrophils and 
maintain the functions of the immune system against infections [227, 233-235]. 
The immune cells in the gut produce a series of extrinsic stimuli, which maintain 
tonic activity of bone marrow HSPCs, as well as neutrophils, monocytes and 
lymphocytes [236].  
 
In turn, the bone marrow can also affect the functions of gut in multiple ways [237-
245]. Recruitment of bone marrow derived-immune cells to the gut elicits acute 
inflammation necessary for host defense [246-248] and contributes to 
inflammation resolution and tissue healing [249-254]. Graft versus host disease 
(GVHD) represents a good example to explain how bone marrow cells affect the 
gut microbiota. After bone marrow transplantation, the immune cells from the donor 
bone marrow may identify the host as “non-self”, therefore causing immune 
rejection. GVHD is reported to inhibit Paneth cell to produce an antimicrobial 
molecule, α-defensins, which plays an essential role in modulating gut microbial 
ecology. The reduced α-defensins cause gut microbiota dysbiosis in GVDH [255, 
256]. NOD 2 has been shown to interact with PGN to stabilize the gut bacteria. 
Alnabhani et. al. showed that the bone marrow specific deficiency of NOD 2 
disturbed the Peyer’s patches homeostasis and led to increased gut epithelial 
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permeability [257]. Tao et. al. used a chimera mouse with the deficiency of bone 
marrow beta1/2 adrenergic receptors (b1/2-ARs) expression and investigated the 
role of the bone marrow sympathetic signaling in gut and microbiota homeostasis 
[258]. Interestingly, the chimera mice exhibited deceased infiltration of CD4+ T and 
NK cells in the gut and alterations of gut microbial composition. Taken together, 
these studies suggested an important role of the bone marrow in the regulation of 




Very interestingly, just like the gut, mouth and skin, the eye also has its own 
community of bacteria in health which protects the eye from invaders [259-261]. 
The microbial community harbors on the ocular surface of the eye. For a long time, 
researchers thought that the ocular surface microbiome had only transiently 
present organisms and did not have a stable microbiome [262]. However, recently, 
investigators have identified by 16S rRNA gene sequencing that there is a wide 
range of homeostatic bacterial species colonized on the ocular surface, confirming 
the concept of a stable ocular surface microbiome [260, 261]. By deep gene 
sequencing, 5 phyla and 59 distinct genera were identified in the ocular microbiota. 
Among those, twelve genera are ubiquitous and abundant among all the subjects 
analyzed and  take in account  96% of the total bacteria [260]. The ocular 
microbiota may be involved in multiple diseases. Sankaridurg et. al. observed a 
change of microbiota composition in subjects wearing contact lens, which may be 
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associated with corneal infiltrative events [263]. Lee et. al. compared the ocular 
microbiota between blepharitis patients and healthy subjects, and also observed 
alterations of microbiota in blepharitis, demonstrating enrichment of Enhydrobacter, 
Streptophyta, and Corynebacterium species [264].  
 
Recently, studies also suggested a role of non-ocular microbiome in ophthalmic 
disease. Astafurov et. al. compared the oral microbiota between patients with 
glaucoma and control subjects. There were higher bacterial counts in glaucoma 
patients compared to controls. In addition, low dose of LPS administration in two 
separate animal models of glaucoma resulted in activation of microglia in the retina 
and glaucomatous neural degeneration, suggesting oral microbiome mediated 
chronic subclinical peripheral inflammation contributes to the pathophysiology in 
glaucoma [265].  
 
It is gradually established that the impaired immune system and chronic intestinal 
inflammation may lead to an enhanced permeability of gut epithelial barrier [266]. 
Research also showed that the microbiota and pathogenic bacteria also damage 
the gut vascular barrier [267]. Accordingly, increased permeability in the gut 
provides the opportunity for the microbiota antigens and even pathogenic bacteria 
themselves to cross the leaky gut into the circulation, and affect distant organs, 
including the eye. Gut microbiota is required for antibody-mediated adaptive 
immunity in response to eye infections. Elisabeth et. al. showed that high fat diet 
alters the composition of microbiota with increased Firmicutes and decreased 
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Bacteroidetes and leads to increased permeability of the gut. Pathogen-associated 
molecular patterns released from the leaky gut into the circulation, resulting in low-
grade inflammation and neovascular age-related macular degeneration [268]. 
Shelton et. al. also showed that microbiota plays an essential role in diet-induced 
choroidal neovascularization. The mice with lower glycemic diet did not develop 
these ocular changes compared to those on a high glycemic diet. Microbiota 
analysis revealed that the acteroidales order and the microbial metabolite, 
secrotonin, protective against retinal changes in mice on a low glycemia diet [269].  
 
Interestingly, gut microbiota-derived antigens can stimulate immune cells, and 
trigger autoimmune uveitis. Horai et. al. demonstrated that the gut commensal 
microbiota-derived antigens bind to autoreactive T cell receptors to activate retina 
specific T cells and provoke an  autoimmunity reaction in the eye [270, 271]. Long 
term administration of oral antibiotics or germ-free environment are able to prevent 
experimental autoimmune uveitis from developing  [272]. All these studies 
suggested an existence of gut-retina axis, which provides us a novel direction for 
studying this gut-retina connection in DR.  
 
Implications for diabetic retinopathy 
 
In summary, all the discussions above suggested that bone marrow, gut microbiota 
and retina are intertwined. RAS can regulate the functions of these organs and 
potentially affect diabetic retinopathy through the bone marrow-gut-retina axis. 
 29 
Here we propose a hypothesis that the bone marrow-gut-retina axis contributes to 
the development of DR (Figure 1-2). Dysregulated RAS results in reduced ACE2 
in the bone marrow and gut and potentially drives the disturbed bone marrow and 
gut communication seen in diabetes. We postulate that the gut will exhibit 
decreased circulating angiogenic cell infiltration, increased the permeability of 
barriers, dysbiosis and increased circulating pathogenic antigens, eventually 
leading to the progression of DR. 
 
We used a T1D model with ACE2 deficiency (ACE2 knockout-Akita mice) to study 
the effects of the protective RAS on bone marrow HSPCs, gut microbial dysbiosis 
and DR.  The project is divided into 3 aims: aim 1 focuses on the role of ACE2 in 
bone marrow hematopoiesis and the function of HSPCs in the context of diabetes; 
aim 2 examines whether the loss of ACE2 in Akita (spontaneously diabetic) mice 
accelerates the development of DR; and aim 3 investigates the role of ACE2 in gut 
microbial dysbiosis and examines the potential links between bone marrow and 
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Figure 1-2. Hypothesis: loss of ACE2 disturbs balance to the bone marrow-gut 





















Chapter 2: The absence of protective RAS axis exacerbated diabetes-




Macro- and micro-vascular complications are the most common complications of 
diabetes, and lead to markedly increased morbidity and mortality [273, 274]. The 
molecular pathogenesis of diabetes involves multiple cell signaling pathways, 
including oxidative stress, inflammation, advanced glycation end products, protein 
kinase C and polyol pathway, which eventually cause increased endothelial cell 
damage [275]. However, unlike the pathways involved in endothelial damage, 
repair mechanisms have been relatively overlooked [222]. Studies have shown 
that HSPCs play an essential role in vascular repair. Besides maintaining 
hematopoiesis, bone marrow-derived HSPCs are released into the circulation in 
response to hypoxia and other stimuli [37, 276]. Circulating hematopoietic cells 
then home to areas of injury and secret paracrine factors to repair the damaged 
vasculature. Circulating hematopoietic cells with pro-angiogenic activity are also 
called  circulating angiogenic cells [26, 277].  
 
HSPCs are considered a good source for autologous cell therapy, especially 
diabetic microvascular complications, because the cells can reach the 
microvasculature. However, autologous HSPCs from diabetic subjects can be 
dysfunctional. Studies showed that in diabetic individuals , peripheral blood HSPC 
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levels are reduced compared to healthy subjects [278, 279]. Data have also 
suggest that diabetes affects the responses of bone marrow HSPCs to tissue 
ischemia or to simulation  by growth factors and cytokines [26, 227]. In addition, 
diabetic HSPCs demonstrated a distinct profile of paracrine factor secretory with 
increased pro-inflammatory factors and reduced stem cell growth factors [26]. 
HSPCs from diabetics also exhibited impaired proliferation and migration 
potentials in both preclinical and clinical studies [26, 93]. Therefore, it is important 
to understand the molecular mechanism of diabetes mediated HSPC defects, and 
to optimize the cells before their use for cellular therapy.  
 
The classic renin angiotensin system (RAS) axis, composed of angiotensin I 
converting enzyme (ACE)/angiotensin II (Ang II)/AT1R, is a key regulator of the 
cardiovascular system, water balance and electrolytes. A novel RAS axis, that 
mainly comprises angiotensin I converting enzyme 2 (ACE2)/Angiotensin 1-7 
(Ang-(1-7))/MAS, counteracts most of the deleterious effects of the classic axis, 
and is considered the “protective” arm of RAS [280]. Existing evidence from our 
group and others suggests that the vasoprotective axis of RAS is also a potential 
target of cell enhancement strategies to restore the function of HSPCs. Our group 
showed that [93] HSPCs from a unique set of diabetic patients without 
microvascular complications, despite more than 40 years of poor glycemic control, 
have higher mRNA levels for vasoprotective RAS genes compared to age, sex and 
glycemic-matched diabetics with microvascular complications. Moreover, lower 
expression of the protective RAS genes is associated with impaired function 
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(migration and proliferation functions) of diabetic HSPCs. Activation of the 
protective RAS axis, by treating HSPCs with Ang-(1-7), increased the production 
of bioactive nitric oxide (NO) and reduced reactive oxygen species (ROS), 
restoring the functions of HSPCs. Similarly, diabetic HSPCs treated with lentivirus-
Ang-(1-7) showed restored vasoreparative function in a mouse retinopathy model 
[216]. These key results suggest that the vasoprotective RAS plays a central role 
in maintaining HSPC functions and vascular repair in diabetes. 
 
In this study, we generated an ACE2 knockout (ACE2KO)-Akita (Ins2WT/C96Y) 
mouse model to test the hypothesis that loss of protective RAS causes a more 
profound defect in hematopoiesis in diabetes.  
 




ACE2 knockout mice were obtained from Dr. Gavin Oudit’s laboratory at the 
University of Alberta. Diabetic heterozygous Ins2Akita (Akita) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME). Male Akita mice were housed in 
the animal facilities at Indiana University School of Medicine, and bred with female 
heterozygous ACE2KO (ACE2+/-) mice to generate ACE2KO-Akita (ACE2-
/YIns2WT/C96Y) male mice, as well as C57BL/6J wild type (WT), Akita and ACE2KO 
mice. Blood glucose levels were measured using an Accu-Chek Compact Plus 
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glucose meter (Roche Diagnostics, Indianapolis, IN). ACE2KO-Akita, Akita mice 
were studied at 3 and 9 months of diabetes. All animal procedures were approved 
by the Animal Care and Use Committee at the Indiana University School of 
Medicine. The mice were anesthetized by inhalation of isoflurane and euthanized 
by decapitation.   
 
Bone marrow Lineage-c-Kit+ (LK) cell isolation  
 
Bone marrow cells were flushed from mouse femur and tibia bones using 
phosphate buffered saline (PBS). Lineage-c-Kit+ HSPCs were selected by the 
lineage negative and c-Kit positive selection kits (Catalog # 19856 and 18757, 
STEMCELL Technology, Vancouver, BC, Canada) using the EasySep™ magnet 




Migration function of HSPCs was analyzed by measuring their ability to migrate 
towards 100 nM CXCL12 (#460-SD-050, R&D Systems, Minneapolis, MN) using 
the fluorimetric QCM 5μM 96-well chemotaxis cell migration assay (5 μM pore size, 
ECM512, Millipore, Temecula, CA). Briefly, 150 μl Ham’s F12 medium with or 
without 100 nM CXCL12 was added to the feeder tray. 20,000 cells were plated in 
the migration chamber in 100 μl Ham’s F12 medium after 30 min pretreatment with 
Ang-(1-7), alamandine or F12 medium (vehicle). The assay plate was then 
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incubated at 37°C in a 5% CO2 incubator for 3 hours when using mouse LK cells 
and 4 hours when using  human CD34+ cells. After incubation, the cells were 
dislodged, lysed in the presence of the CyQuant GR dye solution, and the cell 
lysates were read by Synergy H1 hybrid plate reader using a 480/520 nm filter set 
(BioTek, Winooski, VT). 
 
Bone marrow LK cell proliferation 
 
Proliferation function was measured using the cell proliferation BrdU ELISA kit 
(11647229001, Roche) after 24-hour incubation in serum free stemspan media 
(#09650, STEMCELL Technologies) containing cytokine cocktails (IL-3 0.02 μg/ml, 
IL-6 0.02 μg/ml and stem cell factor 0.05 μg/ml) (#403-ML-010, 406-ML-005 and 
455-MC respectively, R&D Systems, Minneapolis, MN) with or without the 
supplement of 100 nM Ang-(1-7), or alamandine. 
 
Colony forming unit assay 
 
Ammonium Chloride Solution (ACS) lysed bone marrow or blood cells were plated 
in MethoCult™ GF M3434 (STEMCELL Technologies) and then identified 
following manufacturer’s instructions. After vortexing, 1.1 ml MethoCult mixture 
was dispense into each 35mm petri dish from 3 mL syringes with 16 gauge blunt-
end needles. Briefly, cells were diluted in IMDM with 2% FBS to 10× final 
concentrations of plating. Then, the diluted cells were added into pre-aliquoted 
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MethoCult at a ratio of 1:10. The final cell concentrations were 5 × 103 per dish for 




Isolated cells were incubated with rat anti-mouse CD16/CD32 (eBioscience, San 
Diego, California, USA) or 5% rat serum for 15 min at 4 °C. The cells were then 
incubated with primary antibody cocktails for 30 min at 4°C in the dark (FITC anti-
mouse c-Kit, Clone 2B8, Biolegend, Cat# 105806; PE anti-mouse CD34, Clone 
MEC14.7, Biolegend, Cat# 119308; BV421™ anti-mouse lineage cocktail, 
Biolegend, Cat# 133311; PE/Cy7 anti-mouse Sca-1, Clone D7, Biolegend, Cat# 
108114; PerCP-eFluor 710 anti-mouse CD135, Clone A2F10, eBioscience, Cat# 
46-1351-82; APC anti-mouse CD16/CD32, Clone 93, eBioscience, Cat# 14-0161-
82; PE-CF594 anti-mouse CD127, Clone SB/199, BD Biosciences, Cat# 562419). 
After washing, the cells were then stained with flexible viability dye eFluor 780 
(eBioscience, San Diego, California, USA) for 30 min at 4°C, washed with PBS 




Data were firstly evaluated for normal distribution using JMP 9 software. For multi-
group comparisons of normally distributed data, one-way or two-way ANOVA was 
performed followed by an appropriate post hoc t test. If the data was not normally 
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distributed, nonparametic multi-comparisons were used. The data sets were 
considered significantly different if the p value was <0.05. Results were expressed 




Characteristics of the animals 
 
ACE2KO mice exhibited similar random glucose levels as WT mice at the 3-month 
time point. There was a 2.8-fold increase in glucose levels for the Akita group at 3 
months of diabetes in comparison with the WT group. Loss of ACE2 did not 
increase the glucose levels in Akita mice. At the 9-month time point, both Akita and 
ACE2KO-Akita showed a further increase in glucose levels as compared to 3 
months of diabetes, but still, no change was detected in between these two groups 
(Figure 2-1A). All ACE2KO, Akita and ACE2KO-Akita mice showed reduced body 
weight compared to WT mice at both 3- and 9-month time points. Non-diabetic 
groups (WT and ACE2KO mice) had an increase in their body weights over time, 
while 9 months diabetic mice in both Akita and ACE2KO-Akita groups showed 
similar body weights as 3 months of diabetes (Figure 2-1B).  
 
Absence of ACE2 caused depletion of phenotypic short- and long-term 
repopulating HSCs in diabetic bone marrow 
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Both the long-term (LT) and short-term (ST) repopulating HSCs play a key role in 
maintaining hematopoietic cell pool and balance, and represent a reserve for 
HSPCs. To test the ACE2 effects on diabetic bone marrow exhaustion, we 
examined the percentages of HSCs in bone marrow from ACE2KO-Akita mice and 
age-matched controls by flow cytometry. Figure 2-2A showed the gating schematic 
and representative dot plots of flow cytometry analysis. Compared to 3 months 
Akita group, the percentage of bone marrow-derived (ST)-HSCs (Lin-/CD127-/Sca-
1+c-kit+/CD34+CD135-) was increased in ACE2KO-Akita mice. However, ST-HSCs 
percentage was reduced at the 9-month time point in double mutant mice (Figure 
2-2B), suggesting a loss of compensation at the late stage of the disease.  (LT)-
HSCs (Lin-/CD127-/Sca-1+c-kit+/CD34-CD135-) represent the true stem cells of the 
bone marrow and are the most primitive stem cell. Akita mice had a reduction of 
the percentage of phenotypic LT-HSCs, while ACE2KO-Akita mice had a further 
decrease of these cells at 9 months of disease (Figure 2-2C), supporting that loss 
of ACE2 caused a more profound defect of hematopoiesis in diabetes. 
 
Impairment of HSPC migration and proliferation functions in ACE2KO-
Akita mice 
 
Proliferation and migration functions of HSPCs are key indicators of their in vivo 
vaso-reparative ability, because these cells need to self-expand and mobilize from 
the bone marrow in response to chemoattractants at the site of injury. Therefore, 
we next examined whether loss of ACE2 also affects the functions of HSPCs 
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besides the reduction of their reserve pool. The lineage- c-Kit+ (LK) cells isolated 
from the bone marrow represent mouse HSPCs. Akita mice demonstrated reduced 
LK cell proliferation at as early as 3 months of diabetes (Figure 2-3A). The absence 
of ACE2 exacerbated diabetes-mediated impairment of function at both early and 
late stage of disease (Figure 2-3A and B). However, when we treated with either 
100 nM Ang-(1-7) or alamandine, the two main peptides in the protective RAS axis, 
the proliferation function of these cells were largely restored in diabetic cohorts 
even at 9 months of disease (Figure 2-3B). Similar to the proliferation function, LK 
cells from ACE2KO-Akita mice also showed lower migration ability in response to 
the chemoattractant, CXCL12. Ang-(1-7) or Alamandine was able to increase their 
sensitivity to CXCL12 in cells form the 9-month of the diabetic cohort (Figure 2-3C 
and D). These data suggested that the deletion of ACE2 enhanced 
diabetesinduced impairment of HSPC functions, which were essential to prevent 
and repair diabetic retinal vasculature. 
 
ACE2 deficiency led to enhanced myelopoiesis in diabetic bone marrow 
 
Since severe depletion and impaired function of bone marrow HSPCs was 
observed in ACE2KO-Akita cohort at 9-month of diabetes, we next examined 
whether colony forming ability was also impaired in both peripheral blood and bone 
marrow samples using the colony forming assay. After 10 days of culture of ACS-
lysis blood cells, Akita mice showed a significant reduction of total blood colony 
forming units (CFUs) at 9 months of diabetes. The absence of ACE2 led to a further 
 41 
reduction of blood CFUs compared to Akita mice (Figure 2-4A). In the bone marrow 
CFU assays, even though there were no changes in total CFU numbers among 
different genotypes at the 9-month time point, Akita mice exhibited increased 
numbers of CFU-granulocyte/monocyte/granulocyte, monocyte (CFU-G/M/GM) 
compared to WT and ACE2KO mice, suggesting enhanced myelopoiesis in 
diabetic bone marrow. In addition, loss of ACE2 exacerbated this diabetes-
mediated pathological change (Figure 2-4A).  
 
Bone marrow-derived HSPCs give rise not only to myeloid lineages, but also 
lymphoid lineages through the process of hematopoiesis.  Next common lymphoid 
progenitors (CLPs), which are daughter cells of HSPCs and   differentiate into 
lymphoid lineages of blood cells were examined. Figure 2-4B showed the 
representative dot plot of enumerating CLPs by flow cytometry analysis. 
Phenotypic CLP markers Lineage-CD127+Sca-1medc-Kitmed were used. 
Interestingly, the percentage of CLPs was decreased in Akita mice compared to 
WT mice at 9-month time point. A further reduction of the CLP percentage in 
ACE2KO-Akita mice was observed compared to Akita alone (Figure 2-4C). These 
data suggested that diabetes resulted in a shift of hematopoiesis towards 
myelopoiesis with a reduction of CLPs. Thus, ACE2 deficiency enhanced the 







This study reported for the first time that deficiency of ACE2 caused reductions of 
both phenotypic LT- and ST- HSCs in the diabetic bone marrow, adding additional 
understanding to the pathological changes in T1D bone marrow. Consistent with 
our previous findings, ACE2 also affected the migration and proliferation function 
of diabetic HSPCs. Importantly, not only Ang-(1-7), but also alamandine, a newly 
found peptide in the protective RAS, can restore diabetic-induced impairment of 
HSPC functions. Moreover, this study verified that ACE2 plays an important role 
of the imbalance of hematopoiesis in the diabetic bone marrow and results in 
enhanced myelopoiesis and reduced lymphospoiesis. 
 
Our previous study showed that Ang-(1-7) treatment can enhance the migration 
function of CD34+ cells from diabetic patients with microvascular complications 
[93]. Consistent with that, we observed that Ang-(1-7) also restored Akita HSPC 
migration and proliferation function. More importantly, we for the first time showed 
that alamandine has similar beneficial effects on HSPC migration and proliferation 
functions as Ang-(1-7). Alamandine is a newly found peptide in the protective RAS 
axis [4]. Alamandine and Ang-(1-7) are both composed of 7 amino acids. 
Alamandine only has one N-terminal amino acid that is different from Ang-(1-7). 
Unlike Ang-(1-7) binding to MAS receptor, Alamandine binds to a different 
receptor, the MAS-related G protein-coupled receptor, membrane D (MRGPRD) 
[4]. The downstream signaling pathways of MAS involve activation of 
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phosphatidylinositol 3-kinase (PI3K)/Akt and Slit3/ROCK [93, 281]. It is not known 
whether alamandine/MRGPRD share the same signaling pathway as Ang-(1-
7)/MAS. It is important to investigate in the future the underlying mechanisms of 
the beneficial effects of almandine on HSPC functions. 
 
A recent study observed reduced numbers of bone marrow total LSK (Lineage-
Sca-1+c-Kit+) cells in STZ-induced and db/db diabetic mice model [281]. In our 
study, no changes were observed in total LSK cells. This may be due to different 
methodology to assess the numbers or differences in the diabetes models or 
duration of diabetes at the time of examination.  However, when LSK cells were 
further sub-divided into LT-HSCs, ST-HSCs, and multipotent progenitors (MPP), 
we observed that Akita mice showed a significant reduction of LT-HSCs as well as 
a tendency towards a decrease of ST-HSCs. ACE2 ablation contributed to the 
exhaustion of HSCs in diabetes. LT-HSCs and ST-HSCs are critical for maintaining 
the hemostasis of the hematopoietic system and for giving rise to all types of blood 
cells. To further compare the proliferative capabilities of these cell types among 
different genotypes, we plan to do competitive bone marrow transplantation 
studies. 
 
One of our major findings in the study is that loss of ACE2 in diabetes-resulted in 
increased myelopoiesis. By CFU assays, a robust increase in the number of CFU-
G/M/GM in ACE2KO-Akita mice bone marrow was observed. Lymphopoiesis, in 
contrast, was relatively suppressed, as supported by the observations of reduced 
 44 
bone marrow CLP percentages in the double mutant mice. In both T1D and T2D  
animal models, previous studies have demonstrated enhanced myelopoiesis, 
which can drive the production and activation of proinflammatory cells [59, 282]. 
Therefore, the novel role of protective RAS in hematopoiesis adds a new 
dimension to the understanding of pathological mechanisms of diabetes on the 
generation of bone marrow defects. We did not observe a change of total CFUs in 
bone marrow among different cohorts. Because total bone marrow cells were 
plated for CFU assays, which includes not only LT-HSCs and ST-HSCs, but also 
large amounts of progenitors. These progenitors likely contributed to the colony 
forming units instead of the HSCs.  
 
Studies showed that Ang-(1-7) stimulates the forming of erythroid burst-forming 
units (BFU-E) and enhances erythropoiesis [74, 75]. In our ACE2KO-Akita mice, 
we also observed a significant reduction in BFU-E in CFU assay, suggesting a 
protective role of ACE2/Ang-(1-7) RAS axis in erythropoiesis. Interestingly, Ang II 
also has a positive effect on erythropoiesis by increasing EPO levels and sensitivity 
[70, 72]. High-dose of ACE inhibitors also resulted in anemia in human subjects 
reported by two research group [63, 64]. These data suggest that ACE inhibitor-
induced increase in Ang-(1-7) level is not enough to counteract the anaemic effect 
of Ang II loss. 
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In summary, our study demonstrated the beneficial effects of the protective RAS 
on maintaining the numbers and functions of HSPCs and highlights the novel role 


















Figure 2-1. Increased glucose levels, reduced body weight in Akita and 
ACE2KOAkita mice. (A): Random glucose levels were increased in both groups (n 
= 7-9 per group). (B): Diabetic groups showed consistent low body weight, while 
the nondiabetic mice had increased body weight over time (n = 9-18 per group). * 
p<0.05, as compared to WT; # p<0.05, as compared to ACE2KO; & p<0.05, as 
compared to Akita; ** p<0.05, as compared to 3-month time point. Abbreviations: 
WT, wild type; ACE2KO, ACE2 knockout (ACE2-/Y); ACE2KO-Akita, ACE2 
knockout-Akita (ACE2-/YIns2WT/C96Y); 3 mon, 3 months of diabetes and age-
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Figure 2-2. Reduction of both short-term (ST-) and long-term repopulating (LT-) 
hematopoietic stem cells (HSCs) in the bone marrow from ACE2KO-Akita mice at 
9 months of diabetes. (A): Representative scheme of gating for flow cytometry 
enumeration of HSCs. (B): The percentage of ST-HSCs was decreased in 
ACE2KO-Akita mice at the 9-month time point (n = 12-22). (C): The percentage of 
LT-HSCs was reduced in the bone marrow of Akita mice (as compared to WT 
mice). Loss of ACE2 worsened the diabetes-induced reduction of LT-HSC. The 
enumeration was performed at the 9-month time point (n = 12-22). * p<0.05, as 
compared to WT; # p<0.05, as compared to ACE2KO; & p<0.05, as compared to 
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ACE2KO, ACE2 knockout (ACE2-/Y); ACE2KO-Akita, ACE2 knockout-Akita 
(ACE2-/YIns2WT/C96Y); ST-HSC, short-term repopulating hematopoietic stem 
cell; LT-HSC, long-term repopulating hematopoietic stem cell; 3 mon, 3 months of 


















Figure 2-3. Depletion of ACE2 worsens diabetes-mediated impairment of HSPC 
proliferation and migration functions. (A): Impaired proliferation function of HSPCs 
was observed in Akita mice as early as 3 months of diabetes. Loss of ACE2 caused 
a further reduction of proliferation function (n = 5-7). (B): Absence of ACE2 
exacerbated diabetes-induced impairment of HSPC proliferation functions, which 
was restored by the treatment of Ang-(1-7) 100nM or alamandine 100nM (n = 5-
6). (C): Akita mice exhibited a trend toward a decrease in HSPC migration toward 
chemoattractant CXCL12. Ang-(1-7) or alamandine improved the migration of 
diabetic HSPCs (n = 4-6). (D): HSPCs from ACE2KO-Akita mice had no response 
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migration of diabetic HSPCs (n = 4-6). For A-B, * p<0.05, as compared to WT; # 
p<0.05, as compared to ACE2KO; & p<0.05, as compared to Akita; ** p<0.05, as 
compared to no treatment. For C-D, * p<0.05, as compared to WT; # p<0.05, as 
compared to ACE2KO; & p<0.05, as compared to Akita; ** p<0.05, Compared to 
F12/F12; ***, Compared to F12/CXCL12. Abbreviations: WT, wild type; ACE2KO, 
ACE2 knockout (ACE2-/Y); ACE2KO-Akita, ACE2 knockout-Akita (ACE2-















Figure 2-4. Absence of ACE2 worsened the diabetes-mediated imbalance in 
hematopoiesis. (A): Colony forming unit (CFU) assay showed an increased 
number of CFU-G/M/GM when plating bone marrow cells from Akita mice as 
compared to WT mice. A decreased number of total CFUs in Akita group was also 
observed when plating ACS-lysed cells from peripheral blood. Loss of ACE2 
exacerbated diabetes-mediated alterations in both bone marrow and blood CFU 
assay (n = 14-20). (B): Representative gating schema for enumeration of common 
lymphoid progenitors (CLP) (Lineage-CD127+Sca-1medc-Kitmed). (C): The 
percentage of CLPs was reduced in Akita mice at 9-month time point. There was 
a further decrease in CLP percentage in ACE2KO-Akita (as compared to Akita 
alone) (n = 13-22). * p<0.05, as compared to WT; # p<0.05, as compared to 






WT 14 ± 4 48 ± 8 3 ± 2 35 ± 5
ACE2KO 13 ± 3 48 ± 9 1 ± 1* 30 ± 3*
Akita 11 ± 2*# 61 ± 4*# 1 ± 1* 20 ± 4*#
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units; BFU-E, burst-forming unit-erythroid; CFU-G/M/GM, CFU-
granulocyte/monocyte/granulocyte-monocyte; CFU-GEMM, CFU-
granulocyte/erythrocyte/monocyte/megakaryocyte; CLP, common lymphoid 
progenitors; WT, wild type; ACE2KO, ACE2 knockout (ACE2-/Y); ACE2KO-Akita, 


















Chapter 3: RAS mediated changes in HSPCs is associated with more 




Diabetic retinopathy (DR) is the most common microvascular complication (MVC) 
in diabetes and is the leading cause of blindness in American adults [283]. 
Accelerated endothelial cell apoptosis and pericyte loss are two major cellular 
changes of retinal capillaries that occur at a relatively early stage, leading to 
progressive vaso-degeneration [284]. In response to progressive vasoregression, 
the ischemia retina also mounts a pathological angiogenic responses resulting in 
continuous vascular remodeling and eventual progression to the vision threatening 
proliferative DR (PDR) stage [285]. However, the pathological mechanisms 
underlying progressive vasoregression are still poorly understood. To date there 
are no specific treatments beside laser photocoagulation and a pharmacological 
agent that blocks Vascular endothelial growth factor.  
 
Cell therapy is a possible strategy for DR, as it is primarily a small vessel disease. 
It is well-established that HSPCs play an important role in normal vascular repair, 
and therefore represent an ideal source for autologous cell therapy [222]. These 
cells  are mobilized mainly from the bone marrow into the circulation, recruited to 
the injured retinal vasculature in response to ischemia and eventually help to repair 
via paracrine factors [26, 29, 277]. HSPCs from diabetics with microvascular 
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complications are usually dysfunctional and exhibit reduced migration and 
proliferation ability, a different paracrine secretory profile than cells from healthy 
individuals and desensitization to hypoxia [26, 93]. Therefore, the inherent 
dysfunctions of the cells are considered as a possible factor in the initiation of 
vasoregression in DR. However, the underlying mechanisms are still largely 
unknown. 
 
The protective arm of renin angiotensin system is suggested to have beneficial 
effects on HSPCs and retinopathy. Firstly, there was an imbalance of ACE/ACE2 
ratio in the retina of streptozotocin (STZ)-induced diabetic mice [216]. Ang-(1-7), a 
major peptide produced from ACE2 was able to correct the migration and 
proliferation functions of diabetic HSPCs [281]. In addition, gene delivery of ACE2 
protected against the development of retinopathy [216].  is Thus, the 
vasoprotective RAS axis may be a better target than inhibition of the 
classic/deleterous one Existing pharmacological drugs, ACE inhibitorss and AT1 
receptor blockers (ARBs) inhibit the deleterious axis of RAS.  
 
There are four major clinical studies investigating the effects of the classical RAS 
in DR. The goal of the study “Appropriate Blood Pressure Control in Diabetes 
(ABCD)” was to establish blood pressure guidelines for improving diabetic 
complications [286]. The results showed that ACE inhibitor (enalapril) decreased 
DR progression but showed no difference compared to a calcium channel blocker 
(nisoldipine), which suggested that the effects was blood pressure dependent. The 
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Diabetic Retinopathy Candesartan Trial (DIRECT)  tested the effect of the ARB 
(candesartan) on the incidence and progression of DR [287, 288]. It showed that 
candesartan either prevented development or improved mild/moderate DR, but did 
not prevent the progression nor did it cause any improvement in the more 
advanced stages. Another two studies “EURODIAB Controlled Trial of Lisinopril in 
Insulin-dependent Diabetes” and “Renin-Angiotensin System Study”  suggested 
that the effect of RAS blockers depends on the glucose levels of the subjects [289-
292]. Therefore, using RAS blockers for DR treatment was not as successful as 
expected.  
 
However,  ACE inhibitors and ARBs, in addition to inhibiting ACE and AT1R, 
increase Ang-(1-7) [293, 294]. In addition, ACE inhibitors and ARB increase CAC 
numbers in both animal models of hypertension and in individuals with heart 
disease by decreasing senescence, and by increasing proliferation and 
differentiation of HSPCs [295-300]. Ang-(1-7) is shown to improve HSPCs 
regenerative capacity in vitro. Therefore, the beneficial effect of ACE inhibitors and 
ARB on HSPCs may due to the increase of Ang-(1-7). Moreover, ACE2, the key 
enzyme in the protective RAS arm, can convert the deleterious Ang II into 
beneficial Ang-(1-7). Thus, we believe that influencing ACE2/Ang-(1-7)/MAS 
directly would be more efficient as a result of the dual beneficial effect of increasing 
the vasoprotective and decreasing the vasodeleterious axes of the RAS. 
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Akita (Ins2WT/C96Y) mouse is a model of T1D. This autosomal dominant model of 
T1D carries a point mutation in the insulin 2 gene, resulting in inappropriate folding 
of proinsulin and toxicity and dysfunctions of primary pancreatic beta-cells [301]. 
Heterozygous male Akita mice are lean and exhibit hypoinsulinemia and 
hyperglycemia at around 4 weeks of age [301, 302]. Importantly, these mice 
develop diabetic complications, such as neuropathy and nephropathy [303, 304]. 
The Akita mouse is also a good model of retinal complication. Alistair et. al. [305] 
reported that the Akita mouse showed an increase in caspase-3 expression in the 
retina as early as 1 month of diabetes. Akita mice showed increased vascular 
permeability in the retina at 3 months of diabetes when compared to their littermate 
controls. At around 6 months of diabetes, reduced retinal thicknesses of the inner 
plexiform layer, the inner nuclear layer and the ganglion cell layer were observed 
in Akita mice. At 9 months of diabetes, a modest increase in retinal acellular 
capillaries, as well as changes in the morphology of microglia and astrocytes were 
observed, suggesting that Akita mice represent a suitable model for studying the 
progression of DR. 
 
In this study, we validated our hypothesis that the absence of ACE2 is a key initial 
event that leads to the development DR in a genetically modified mouse model. 
We also tested in human subjects that loss of the protective RAS influences 








Male Akita (Ins2WT/C96Y) mice (the Jackson Laboratory, Bar Harbor, ME) were bred 
with female heterozygous ACE2KO (ACE2KO+/-) mice (obtained from Dr. Gavin 
Oudit’s laboratory) to generate ACE2KO-Akita male mice, as well as age-matched 
controls (wild type, ACE2KO and Akita mice). All the mice were housed and bred 
in the animal facilities at Indiana University School of Medicine (IUSM). All the 
experiments and procedures were approved by the animal care and use committee 
at IUSM (animal protocol # 11165).  Diabetic mice were studied at 3 months and/or 




Electroretinogram (ERG) were performed on mice after overnight dark-adaption 
using an UTAS-E 2000 ERG system (LKC Technologies, MD, USA). Scotopic rod 
signaling was assessed with 10 increasing intensities of white light. Photopic cone 





Optical coherence tomography 
 
Optical coherence tomography (OCT) was performed using a InVivoVue OCT 
system (Bioptigen, Inc., NC) as previously described [306]. Before the 
measurement, eyes were dilated by 2.5% phenylephrine hydrochloride and 1% 
atropine. High-resolution three lateral B-scan images were obtained in 
anesthetized mice. 
 
Acellular capillaries quantification 
 
Trypsin digestion of retina was performed according to a protocol reported 
elsewhere (Stem Cells. 2016 Feb; 34(2): 405–417.). Briefly, 4% PFA fixed retinas 
were isolated and incubated with 3% trypsin 1:250 (Cat. # 27250018, Gibco, 
Carlsbad, CA) at 37°C for 1-2 hours. After trypsinization, the internal limiting 
membrane and adjacent tissues were carefully removed under the microscope. 
Retinas were mounted on slides and stained with the periodic acid-Schiff’s base-




All human studies were approved by the Institutional Review Boards at the 
University of Florida (Study # RAAS 535-2011). Study subjects were recruited as 
healthy controls or diabetics with either no DR, mild non-proliferative DR (NPDR), 
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moderate NPDR or severe NPDR from clinics at the University of Florida or the 
Eugene and Marilyn Glick Eye Institute at IU School of Medicine Indiana University. 
Diabetic individuals included both males and females with either T1D or T2D. The 
degree of DR was assessed using color fundus imaging and fluorescence 
angiography. Peripheral blood was obtained for plasma collection and CD34+ cell 
isolation. 
 
Measurement of plasma Ang-(1-7) levels 
 
Peripheral blood was collected in heparin-coated tubes (#367963, BD 
Biosciences) and place on ice immediately after collection. Plasma was obtained 
by centrifugation at 700 g, 4°C for 20 min and snap frozen in liquid nitrogen. The 
samples were then sent to Attoquant Diagnostics GmbH (Vienna, Austria), where 
Ang-(1-7) levels were quantified using a combination of ultra-pressure-liquid 
chromatography and mass spectrometry (LC-MS/MS) [307]. Stable-isotope-
labeled internal standard controls were used to correct the peptide recovery due 
to sample preparation for each individual sample.  
 
Enrichment of human CD34+ cells  
 
120 ml peripheral blood was diluted with PBS (1:1). Then, every 25 ml-diluted 
blood sample was gently overlaid on 12.5 ml Ficoll-Paque Plus (Cat. # 17-1440-
02, GE Healthcare) into 50 ml tubes. After centrifugation at 800 g for 30 min, buffy 
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coat was transferred into a new 50 ml tube and washed three times with PBS 
containing 2% FBS and 1mM EDTA. Peripheral blood mononuclear cells were then 
enriched for CD34+ cells by the human CD34 positive selection Kit (Cat. #18056, 
StemCell Technologies) using EasySep™ magnets. Enriched CD34+ cells were 




Total RNAwas extracted from human CD34+ cells using RNeasy Mini Kit (Qiagen, 
Valenicia, CA). RNA concentration and quality were determined using Nanodrop 
(Thermo Scientific, Wilmington, DE). cDNAs were synthesized by iScriptTM cDNA 
synthsis kit (BioRad, Pleasanton, CA). Quantitative PCR were performed using 
SYBR Green (Qiagen, Valenicia, CA) with MAS primers (PPH10808A, Qiagen, 
Germantown, MD). Results were expressed as 2^ (delta Ct) *100 relative to their 
internal controls. 
 
Blood pressure measurement  
 
After anesthesia with 1.5% isoflurane, mice had a thin catheter placed into their 
carotid artery. The catheter was connected to a transducer which converted the 
blood pressure signals into electrical signals (DMD4059, OMEGA Engineering, 
Nerwalk, CT). Then, the signal of mean blood pressure was recorded by pressure 
precision T1600 software. 
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Isometric tension recordings 
 
Isometric tension experiments were performed as previously described [308, 309]. 
WT, Akita, ACE2KO and ACE2KO-Akita mice were used. The mouse aortas were 
isolated and cleaned from the connective tissue and fat. The aortic arches were 
cut into (1-3 mm) rings. The rings were then placed into organ baths, which 
contained oxygenated (saturated with a gas mixture of 95% O2 and 5% CO2) 
Krebs buffer maintained at 37°C. The Krebs buffer was a solution containing 131.5 
mM NaCl, 5 mM KCl, 2 mM CaCl2, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 25 mM 
NaHCO3, and 5 mM glucose. The optimum length was determined as described 
elsewhere [310].  
 
Data analysis  
 
Data were analyzed by JMP 9 software and expressed as mean ± SE. One-way 
ANOVA was used if comparing multi-group with only one time-point. Two-way 
ANOVA was used if comparing different genotypes with multiple time points. Then, 
an appropriate post hoc t test was performed after ANOVA. Nonparametic multi-
comparisons were performed if the data was not normally distributed. P value 







Diabetic mice exhibited reduced retinal thickness  
 
Color fundus photographs were used to examine the interior surface of eyes from 
different types of mice.  Interestingly, ablation of ACE2 led to a robust increase in 
the number of white lesions in the retina, irrespective of a diabetic background 
when comparing Akita alone at 9 months of diabetes and age-matched WT mice 
(Figure 3-1A). We then examined retinal thickness by OCT in a cohort of mice. 
Figure 5B showed representative OCT images of each genotypes. Both Akita and 
ACE2KO-Akita groups exhibited thinner retinal thickness (~9.2% reduction) in 
comparison with their non-diabetic controls by OCT at 9 months of diabetes (Figure 
3-1C), suggesting vasodegeneration in the diabetic retina. 
 
ACE2KO-Akita showed progressive retinal electrical responses over the 
duration of diabetes 
 
ERGs measure the electrical responses of different retinal cell types and provides 
information about the retinal function. Scotopic a wave records the signal of rod 
photocurrents, while scotopic b wave reflects the signal generated by depolarizing 
bipolar cells and Müller cell currents [311]. In Figure 3-2A and B, diabetic groups 
demonstrated similar scotopic a- and b- wave amplitudes when compared to 
nondiabetic groups, except the Akita mice had a slight increase of a-wave 
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amplitude as compared to ACE2KO mice. At 9 months of diabetes, Akita mice 
showed reduced scotopic b wave and no change in a wave compared to WT mice. 
In addition, only loss of ACE2 caused a progressive reduction of both scotopic a- 
and b- waves over the duration of diabetes, suggesting ACE2 ablation worsen 
diabetic retinal functions (Figure 3-2A and B). 
 
Deficiency of ACE2 exacerbated diabetes-induced increase in acellular 
capillaries 
 
Acellular capillaries were quantified from trypsin digests and PAS staining of the 
retinal vasculature which are defined as basal membrane tubes lacking endothelial 
cell and pericyte nuclei. Figure 3-3A shows representative retinal vascular images 
from different cohorts of mice at both 3-month and 9-month time points. No change 
was observed among the different genotypes at the 3-month time point. A 
significant increase in acellular capillary numbers was seen in the Akita mice at 9 
months of diabetes. Interestingly, the lack of ACE2 resulted in a more robust 
increase in the pathological phenotype than the Akita alone (Figure 3-3B). These 
data suggest that ACE2KO-Akita mice had a more advanced retinopathy 
compared to the Akita mice. Thus, ACE2 loss clearly exacerbated the 
microvascular defects observed in the diabetic retina. 
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Deficiency of ACE2 did not worsen diabetes-induced endothelial 
dysfunction of microvasculature 
 
Classic RAS is well known as a key regulator of cardiovascular function and 
hypertension. We also examined the effects of protective RAS on hypertension. 
The mean arterial blood pressure levels were measured in a cohort of mice using 
carotid artery catheterization. No difference in arterial blood pressure readings was 
observed in Akita mice as compared to WT group. Unexpectedly, loss of ACE2 
also did not result in systemic hypertension in either diabetic ACE2KO-Akita mice 
at 3 months of diabetes or age matched ACE2KO mice (Figure 3-4A). Similar blood 
pressure measurements were obtained in these four cohorts at 9 months of 
diabetes (Figure 3-4A). Endothelial function and reactivity in aortic rings from the 
same four cohorts of mice was assessed. At 9 months of diabetes, aortic rings 
from Akita mice exhibited increased sensitivity to phenylephrine, a vasoconstrictor, 
compare to both WT and ACE2KO groups (Figure 3-4B). Aortic rings of ACE2KO-
Akita exhibited a similar level of increased sensitivity to phenylephrine as the Akita 
mice. Phenylephrine pre-contracted aortas demonstrated that Akita mice showed 
significant endothelial dysfunction when challenged with acetylcholine as 
compared to aortas of WT mice. ACE2KO-Akita mice exhibited a similar degree of 
endothelial dysfunction as aortas from Akita mice (3-4C), whereas endothelial 
function in aortas of ACE2KO mouse was similar to that of the aortas of WT mice. 
These data suggest that while the diabetic aortas exhibit profound endothelial 
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dysfunction and markedly increased sensitivity to catecholamines, loss of ACE2 
did not worsen this dysfunction.  
 
Impaired HSPC migration function is associated with different stages of 
DR and can be corrected by restoring its Ang 1-7 levels in human subjects 
 
CD34+ cells are considered as human HSPCs in the circulation. Inadequate 
vascular repair of HSPCs plays an important role in the progression of DR. The 
protective RAS has been reported to help maintain the functions of diabetic 
HSPCs. Therefore, we next accessed whether human CD34+ cell function is also 
associated with deficiency of the protective RAS and reflects the severity of DR. 
Peripheral blood CD34+ cells were isolated from healthy subjects, diabetics with 
no microvascular complications or those with different stages of DR (Figure 3-5A). 
Systemic RAS levels were measured in the human cohorts. No change was 
observed in Ang II levels in diabetics with no complications or with DR as compared 
to healthy subjects. Interestingly, in healthy controls, Ang-(1-7) levels were all very 
low (less than 2.4 pg/ml). However, it was elevated in individuals with no 
microvascular complications and reduced in those with DR, suggesting a loss of 
Ang-(1-7) compensation in DR (Figure 3-5B). MAS is the receptor for Ang-(1-7). 
Consistent with plasma Ang-(1-7) levels, we showed that MAS gene expression 
was also dramatically increased in CD34+ cells from diabetics with no 
microvascular complications, while significantly reduced in those with DR (Figure 
3-5C). Then, we accessed the migration function of human CD34+ cells toward the 
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chemoattractant CXCL12. CD34+ cells isolated from healthy subjects or diabetic 
patients with no complications responded well to this chemoattractant. However, 
even with the onset of DR, CD34+ cells exhibited impaired migratory function. In 
the severe NPDR subjects, CD34+ cells nearly had no response to CXCL12. When 
the cells were treated with Ang-(1-7), the migration functions were restored even 




In the study, loss of ACE2 resulted in advancement of retinopathy in a diabetic 
mouse model, as ACE2KO-Akita mice showed a significant increase of retinal 
acellular capillaries and a reduction of both scotopic a- and b- waves on ERG when 
compared to Akita alone at 9-months of disease. However, loss of ACE2 did not 
worsen diabetes-induced endothelial dysfunction of aorta rings. In our clinical 
study, we provided evidence that the severity of retinopathy is associated with 
dysfunctional HSPC migration ability. In addition, Ang-(1-7) treatment improved 
the impaired migratory function of HSPC from NPDR subjects.  
 
It is well known that poor glycemic control and long-standing diabetes typically 
promotes the development of diabetic microvascular complications, including 
retinopathy. Consistent with studies by other groups [305, 312], we also observed 
that Akita mice developed DR  at a late stage of diabetes. Currently multiple factors 
and mechanisms have been suggested as causative in modulating 
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vasodegeneration in DR, including inflammation, impaired HSPC and increased 
circulating lipids and fatty acids. We  and others  have shown that the imbalance 
of RAS within HSPC may be a causative in their  impaired function [93, 281]. These 
previous studies have mainly focused on the effects of ACE2 on HSPCs. In this 
study, an ACE2 knockout genetic model was generated to directly address the 
question that whether ACE2 plays an essential role in the development of DR. We 
also showed that the beneficial retinal effect of ACE2 may be associated with its 
favorable effects on HSPCs. 
 
We observed that loss of ACE2 accelerated the diabetes-mediated increase in 
acellular capillary numbers, suggesting ACE2 plays an important role in diabetes- 
induced pathological changes. It is worth noting that in rodent models of diabetes, 
the hallmark, microanuerysms, does not usually occur on fundus images. In 
addition, it also does not naturally progress to PDR stage. These differences in 
pathogenesis in rodent models partially limited study on specific features and 
translation to human subjects.  
 
When we examine the mice using color fundus, only ACE2 knockout mice had an 
increase of the white lesions while no change was observed in the Akita mouse. 
Consistent with the fundus data, we observed that ACE2 loss also led to reduced 
amplitude in both scotopic a- and b- waves while Akita mice only showed reduced 
scotopic b wave at late stage of diabetes. These results suggest that ACE2 may 
have some direct effects on the neural retina independent of diabetes. However, 
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since we did not examine these lesions histologically they may represent 
something other than neural infarcts and may be small inflammatory lesions 
composed of macrophages and lymphocytes [313], [314]. To further understand 
this phenomenon, immunohistochemistry staining should be performed to show 
the abnormalities at structural and cellular levels. In addition, ganglion cells are an 
important cell type in the neuron retina. Retina ganglion cell markers, including 
Brn3b, Math5, Islet1 and γ-synuclein, can be stained on the retinal cross-sections 
by immunofluorescence staining [315]. Numbers and morphologic abnormalities 
should be assessed in the retinal ganglion cell layers to observe any changes in 
the neuron retina in the ACE2 knockout mice.  
 
Another very interesting finding is that both ACE2KO and ACE2KO-Akita mice 
exhibited normal mean blood pressure level, which was similar to wild-type mice. 
It is well established that classic RAS is a key regulator of blood pressure. In the 
clinic, there are several medications that target the classic RAS, including ACE 
inhibitors and AT1 receptor blocker (ARB) which have a beneficial effect in blood 
pressure control for hypertensive patients. However, the effects of the protective 
RAS are still controversial, as contradictory results have occurred in animal 
studies. At least three different lines of ACE2 knockout models exist  [316]. The 
first group that reported ACE2KO mice described normal blood pressure in on the 
mice at 3 months of age when compared to their WT littermates [317]. Moreover, 
even treating those mice with an ACE inhibitor, the ACE2KO mice still exhibited 
blood pressure reduction to a similar extent as that was observed in WT control 
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mice. Yamamoto et al. obtained similar results as the previous group using a 
distinct ACE2KO mouse line, while a third group observed that only their C57/BL6 
background ACE2KO mice showed a mild increase in blood pressure (~7 mmHg) 
[318, 319]. We used carotid artery catheterization to measure the mean blood 
pressure and we did not observe any change of blood pressure in the ACE2KO 
mice even with a C57/BL6 background. Therefore, in addition to the genetic 
background, different methods used for measurement of blood pressure and 
environmental factors may contribute to different results by various group. Taken 
together, all the data suggested that, unlike classic RAS, the protective RAS may 
have very limited effects on blood pressure. 
 
Several independent groups have reported that ACE2KO mice exhibited normal 
cardiac function, suggesting a non-essential role of ACE2 in regulating 
physiological cardiovascular function or a  compensatory mechanism of the RAS 
in normal condition [318, 320]. Yemamota et al. reported that ACE2 deficiency 
caused cardiac abnormalities as accessed by echocardiography after pressure-
overload, indicating ACE2 is important in cardiac function modulation under 
specific stress [319]. Patel et al, observed that ACE2KO mice fed a high fat diet 
exhibit epicardial adipose tissue inflammation and impaired cardiac diastolic 
dysfunction by left ventricular pressure-volume analysis [321]. Patel et al. also 
observed systolic dysfunction in ACE2KO-Akita mice by echocardiographic 
assessment [322]. In addition, they also showed that Akita mice had a similar 
response to transient ischemia-reperfusion, while ACE2KO-Akita mice had 
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changes in flow-mediated vasodilation of the femoral artery in mice with 6 months 
of diabetes.  However, in our study, we also used Akita as a model of chronic 
stress. Although diabetic mice exhibited increased vaso-contraction in response to 
PE and impaired vasodilation function of the aorta rings, ACE2 deficiency did not 
worsen the diabetes-induced alterations of aorta function. Our results suggest that 
ACE2 may not be necessary for regulation of diabetes-mediated macrovascular 
dysfunction.  The inconsistency of the results in the same animal model may be 
due to the different ages of mice used.  In Patel et. al, the diabetic mice had 6 
months of disease, while we studied macrovascular function at 9 months of 
diabetes. In their study, the Akita mice alone at 6 months of diabetes did not show 
a significant change in flow-mediated dilation. In our study, we observed at 9 
months of diabetes, even Akita alone has shown clear differences in PE-induced 
contraction and ACh-mediated dilation as compared to age-matched wild type.   
 
In our clinical studies, we demonstrated that there was a higher level of plasma 
Ang-(1-7) and increased MAS gene expression in HSPCs in diabetic patients with 
no microvascular complications. These findings are consistent with other reports 
that showed activation of protective RAS in mouse kidney and heart tissues at an 
early stage of diabetes, suggesting a compensatory  response to diabetes-
mediated stress [323-326]. It is also worth noting that not only did HSPCs have 
impaired migratory function in NPDR, but the extent of the dysfunction was 
associated with the severity of retinopathy. To further establish the role of bone 
marrow-derived HSPCs and retinopathy, bone marrow cells from ACE2KO mice 
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could be transplanted into the Akita mice and the mice could be observed for 
development of more severe DR than mice transplanted with WT cells. 
 
In summary, by using an ACE2KO diabetic model, our data provide direct evidence 
that the protective RAS plays an essential role in DR. The data from the human 
subjects demonstrates that the loss of the protective RAS within HSPC may be the 
causative of the progression of DR and may serve as a novel therapeutic target 
















Figure 3-1. Reduced retinal thickness in Akita mice at 9 months of diabetes. (A): 
There were increases in white lesions in both ACE2KO and ACE2KO-Akita groups 
by color fundus photography (n = 4-5 per group). (B): Representative images of 
retina near the optic nerve on optical coherence tomography (OCT). (C): Reduced 
retinal thickness was observed in both Akita and ACE2KO-Akita mice at the 9-
month time point, but there was no difference between the groups (n = 8 per 
group). * p<0.05, as compared to WT; # p<0.05, as compared to ACE2KO. 
Abbreviations: OCT, optical coherence tomography; WT, wild type; ACE2KO, 
ACE2 knockout (ACE2-/Y); ACE2KO-Akita, ACE2 knockout-Akita (ACE2-
/YIns2WT/C96Y). 
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Figure 3-2. Reduced electrical responses of retinal cells in ACE2KO-Aktia mice. 
(A): There was no change in scotopic a-wave in Akita mice at 9-months of diabetes 
which reflects the electrical signal of the rod photoreceptors. Loss of ACE2 caused 
a decrease in scotopic a-wave amplitude in Akita mice at a late stage of diabetes 
(n = 5-7). (B): Both Akita mice and ACE2KO-Akita mice had a reduction of scotopic 
b-wave, indicating low electrical responses of depolarizing bipolar cells and Müller 
cells. Only ACE2KO-Akita mice showed a reduction of both scotopic a- and b- 
wave over the duration of diabetes (n = 5-7). * p<0.05, as compared to WT; # 
p<0.05, as compared to ACE2KO; & p<0.05, as compared to Akita; ** p<0.05, as 
compared to 3-month time point. Abbreviations: ERG, electroretinogram; WT, wild 
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Figure 3-3. ACE2 deletion worsens diabetes-induced acellular capillaries at 9 
months of diabetes. (A): representative images of retinal vasculature and acellular 
capillaries (arrow) in the different genotypes at both 3-month and 9-months. (B): 
Increased numbers of acellular capillaries was observed in Akita mice. ACE2KO-
Akita mice had a further increase in acellular capillary number (as compared to 
Akita mice), suggesting more advanced retinopathy (n = 7-12 per group). * p<0.05, 
as compared to WT; # p<0.05, as compared to ACE2KO; & p<0.05, as compared 
to Akita; ** p<0.05, as compared to 3-month time point. Abbreviations: WT, wild 
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Figure 3-4. Loss of ACE2KO did not exacerbate diabetes-mediated endothelial 
dysfunctions of macrovasculature. (A): ACE2KO-Akita mice exhibited similar mean 
blood pressure levels as Akita alone at both 3 or 9 months of diabetes (n = 3-8 per 
group). (B): Akita aorta rings exhibited increased sensitivity to phenylephrine (PE) 
at 9 months of diabetes. Aorta rings from ACE2KO-Akita mice responded similarly 
to PE as Akita alone. (C): Akita aorta rings exhibited impaired vasodilation 
response to acetylcholine (ACh) at 9 months of diabetes. Loss of ACE2 did not 
worsen the Akita-induced vascular dysfunction. * p<0.05, as compared to WT; # 
p<0.05, as compared to ACE2KO; & p<0.05, as compared to Akita; ** p<0.05, as 
compared to 3-month time point. Abbreviations: PE, phenylephrine, Ach, 
acetylcholine, WT, wild type; ACE2KO, ACE2 knockout (ACE2-/Y); ACE2KO-Akita, 
ACE2 knockout-Akita (ACE2-/YIns2WT/C96Y); 3 mon, 3 months of diabetes and age-
matched control; 9 mon, 9 months of diabetes and age-matched control. 
 77 
 
Figure 3-5. Loss of the protective RAS axis and impaired migratory function of 
































































































(A): Basic characteristics of the control and diabetic subjects recruited. (B): plasma 
Ang II and Ang-(1-7) peptide levels in health control, diabetes with no 
complications (DM-NC), and diabetes with NPDR. Ang-(1-7) level was increased 
in DM-NC followed by a reduction at NPDR stage (n = 5-10). (C): MAS, receptor 
for Ang-(1-7) was also increased in CD34+ cells from DM-NC patients, but reduced 
in those from NPDR subjects (n = 5-17). (D): Impaired migration ability of CD34+ 
cells was observed at the onset of NPDR. The severity of impaired CD34+ cell 
migration function was associated with different stages of NPDR, which can be 
restored by Ang-(1-7) treatment (n = 3-12). For A and C, * P < 0.05 as compared 
to control; & P<0.05 as compared to DM-NC. For D, * P < 0.05 as compared to 
control; ** P<0.05 as compared to CXCL12+Ang (1-7) group; # P < 0.05 compared 
to no treatment group. Abbreviations: DM-NC, diabetes with no complications; 


















Chapter 4: ACE2 deficiency led to alterations in gut microbiota composition 




The intestinal microbiota describes all living organisms present in the 
gastrointestinal (GI) tract. These bacteria play an important role in physiological 
functions, such nutrient digestion and absorption, vitamin biosynthesis, 
metabolism modulation and immune regulation [327-330]. The intestinal microbes 
and human host interact with each other and co-evolve, together resulting in the 
development of intact immune mechanisms for host defense and for maintaining  
metabolism [331, 332]. Therefore, the disturbance of gut microbiota homeostasis 
has been considered as an independent risk factor and integral determinant of 
human diseases.  
 
As the growing evidence and studies about the role of microbiota, our 
understanding of diabetes pathogenesis is also expanded from the genetic factors 
and contribution of high fat diet to studies of the effect of microbiota antigens and 
metabolites. Recent researches on both animal models of T1D  and human T1D 
subjects indicate that gut microbiota is strongly associated with the development 
of T1D. Reduced ratio of Firmicutes to Bacteroidetes has been observed in the 
Bio-Breeding diabetes-prone rats and antibiotic treatments can partially protect 
from T1D [333]. The alteration of Firmicutes and Bacteroidetes ratio has also been 
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found in (pre)diabetic children by 2 independent groups [97, 98]. Alterations of gut 
microbiota produced metabolites also contribute to the development of diabetes, 
such as decreased short chain fatty acids (SCFA) [101], increased trimethylamine 
N-oxide (TMAO) [334], as well as increased LPS and PGN [103, 111]. However, 
the underlying mechanisms of gut microbiota changes in diabetes remain largely 
unknown. 
 
RAS plays a vital role in regulating many physiological processes of the 
vasculature. Ang-(1-7) acting through the Mas receptor mediates its vasoprotective 
effects by activation of endothelial nitric oxide synthase (eNOS) through an Akt-
dependent mechanism and attenuation of NADPH oxidase [93]. Growing evidence 
has suggested a role of RAS in the alterations of gut microbiota. Using an ACE2 
knockout models, Tatsuo et. al. demonstrated loss of ACE2 resulted in a 
dramatically reduced plasma tryptophan level and an imbalance of amino acid 
homeostasis through downregulation of B0AT1 expression level leading to a  
change of gut microbiota and increased susceptibility to colitis [161].  ACE2 
deficiency leads to advanced DR and bone marrow defects. But it is still unclear 
whether ACE2 also play an important role in the change of gut microbiota in the 
context of diabetes. 
 
In this study, we hypothesized that Akita mice had an alteration of their microbiota 
composition compared to WT mice. By using ACE2 knockout (ACE2-/Y, ACE2KO) 
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Akita model, we further studied the role of ACE2 in the modulation of microbiota 
composition and alteration of functional gene pathways in diabetes. 
 




ACE2 knockout (ACE2KO) mice were generated and obtained from Dr. Oudit’s 
laboratory at University of Alberta, Canada. Then, ACE2KO heterozygous female 
mice (ACE2-/+) were bred with male heterozygous Ins2WT/C96Y (Akita) diabetic mice 
(Bar Harbor, ME) at Indiana University School of Medicine. After breeding, 
AEC2KO-Akita (ACE2-/Y/Ins2WT/C96Y) mice and ACE2KO mice were generated, as 
well as Akita and WT (wild type) mice that were used as littermate controls. PCR 
using ear tissues were used to confirm different genotypes. Primers for ACE2 
gene: Forward- CCG GCT GCT CTT TGA GAG GAC A; Reverse- CTT CAT TGG 
CTC CGT TTC TTA GC. Primers for ACE2KO detection: Forward- CCG GCT GCT 
CTT TGA GAG GAC A; Reverse- CCA GCT CAT TCC TCC CAC TC. Primers for 
Akita mutation: Forward- TGC TGA TGC CCT GGC CTG CT; Reverse- TGG TCC 
CAC ATA TGC ACA TG. For Akita mice genotyping, restriction digestion was 
performed using Fnu4HI after PCR. ACE2KO-Akita mice and Akita mice were 
studied primarily at 9-months of diabetes and age-matched control groups (WT 
and ACE2KO). All animal procedures were approved by the animal care and use 
committee at the Indiana University School of Medicine. 
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16S rRNA gene sequencing 
 
Fecal, eye, bone marrow supernatant and plasma samples were collected and 
shipped to Wright Labs, LLC. Genomic DNAs were extracted (approximately 0.25 
g per sample) using a MoBio Powerfecal DNA Isolation kit following the 
manufacturer’s instructions (MoBio Carlsbad, CA). The Disruptor Genie cell 
disruptor (Scientific Industries, Bohemia, NY) was used to vortex the samples. The 
isolated genomic DNAs were then eluted in 50 μl of 10 mM Tris and quantified 
using the Qubit 2.0 (Invitrogen) Fluorometer according to the protocol of the 
dsDNA High Sensitivity option. PCR was performed using 10 ng of template DNA 
at a total volume of 25 μl per reaction. After PCR amplification, the products were 
then purified using the Qiagen Gel Purification Kit (Qiagen, Frederick, MD). After 
quality check using the 2100 Bioanalyzer DNA 1000 chip (Agilent Technologies, 
Santa Clara, CA), pooled libraries were then shipped to the California State 
University (North Ridge, CA) for sequencing. After quantification using the Qubit 
High Sensitivity dsDNA kit (Life Technologies, Carlsbad, CA) and dilution, pooled 
libraries were loaded on an Illumina MiSeq V2 500 cycle kit cassette with 16S 
rRNA library sequencing primers and set for 250 base, paired-end reads. Raw 
sequence data was successfully obtained in all the samples sent. Paired-end 
sequences were trimmed at a length of 250 bp, and quality control was set as an 
expected error of less than 0.005 by USEARCH V7. Reads were then analyzed by 
the QIIME 1.9.0 software. USEARCH61 algorithm was used to identify chimeric 
sequences and to pick open reference operational taxonomic units (OTUs). 
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Taxonomy was assigned using the Greengenes 16S rRNA gene database (13-5 
release, 97%) and organized into a BIOM formatted OUT table, which was 
summarized within QIIME 1.9.0. 
 
Alpha diversity analysis 
 
The plots of alpha diversity were generated within the Phyloseq sequence analysis 
package using a rarified OTU table. Rarefaction was performed on sequences 
across all samples. Alpha diversity plots were generated using different metrics, 
including Chao1, ACE, Shannon’s Diversity, Simpson, Inverted Simpson and 
Fisher’s richness metrics. 
 
Beta diversity analysis 
 
ANOSIM significance tests and principal coordinates analyses (PCoA) plots were 
generated from a weighted UniFrac distance matrix from a CSS normalized OTU 
table within QIIME 1.9.0. The data was then uploaded to the online analysis tool 








BIOM formatted OTU table was used to organize assigned taxonomy. To identify 
the abundance of prevalent phyla, facet grid bar plots were generated within 




Relative abundances of taxa were multiplied by 1 million and formatted as 
described before [335]. Comparisons were made with “Sample Type” as the main 
categorical variable (“Class”). Alpha levels of 0.05 were used for both the Kruskal–
Wallis and pairwise Wilcoxon tests. Linear Discriminant Analysis (LDA) scores 
greater than 3.0 are displayed. 
 
Metatranscriptome analysis of fecal samples 
 
Fecal samples (n=16) underwent MoBio (Qiagen, CA) RNA extraction. 
Subsequent Nugen Ovation (Nugen, CA) transcriptome library was prepared for 
all fecal samples and quality of the library was checked using a high sensitivity 
bioanalyzer chip (Agilent, CA). Then, the library was purified using QIAquick gel 
purification kit (Qiagen, CA) after equimolar amounts were pooled. After 
purification, libraries underwent sequencing on the Illumina HiSeq4000 following a 
2 x 150 index run. Quality assessment of the raw sequencing data was performed 
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using the program FastQC. A sliding window filtration within the program 
Trimmomatic were utilized to filter the sequence data, then human DNA reads 
were also removed from the filtered sequence data. The metatranscriptome 
analysis tool Metaphlan was implemented to quantify the taxonomic profile within 
each sample. To obtain functional gene profiles, filtered data was annotated using 
the Uniref90 database within Humann2. Uniref90 annotations were regrouped as 
KEGG orthology (KO) terms, which consequently underwent CPM (counts per 
million) normalization within Humann2 for stratified barplot analysis and LefSe 
enrichment plots. Functional count data was also uploaded to the online analysis 
tool METAGENassist for PLS-DA analysis. 
 
Small intestine lamina propria (LP) cell isolation 
 
Mouse small intestines were collected and flushed with cold PBS. The intestine 
was cut open along its length and then into 1.5 cm pieces, after removing Peyer 
patches. The intestine pieces were washed with cold PBS three times and 
incubated with 10% FBS in PBS with 20 mM HEPES and 10 mM EDTA in PBS for 
25 min at 37°C. After incubation, the tissue was washed with PBS three times while 
placed on ice, and then digested using collagenase D (2 mg/ml) and DNase II (10 
ug/ml) in 10 ml RPMI1640 medium for 1 hour at 37°C. The digested tissues were 
collected and filtered through a nylon mesh to remove cell aggregates and debris. 
The resulted filtrate was centrifuged at 500 g to pellet cells. The pellet was 
resuspended in 10 ml 40% Percoll (GE Healthcare) and overlaid on 10 ml 75% 
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Percoll. Lamina propria (LP) cells were collected at the interphase of the Percoll 
layers after centrifuging at 2000 rpm at 23°C for 20 min. The LP cells were washed 
with 2% FBS in PBS buffer (supplemented with 1mM EDTA) twice. One million 
cells were used for each FACS analysis. 
 
Gut blood flow recovery measurement 
 
The intestinal ischemia-reperfusion experiments were performed as described 
elsewhere (cite: shock July 2016 - Volume 46 - Issue 1 - p 75–82). Briefly, 
anesthetized mice were placed on a heating pad. The abdominal skin was 
prepared by hair removal lotion. The root of the mesenteric artery was located and 
occluded for 30 minutes by a microvascular clamp. After ischemia, the clamp was 
removed for blood flow reperfusion for 60 minutes. Intestinal blood flow was 
recorded by Laser Doppler imaging (Moor Instruments, DE) at baseline, at the time 
of ischemia, and immediately the following reperfusion or at 60 minutes after 
reperfusion.   
 
Flow cytometry analysis 
 
Isolated cells were incubated with rat anti-mouse CD16/CD32 (eBioscience, San 
Diego, California, USA) for 15 min at 4 °C. The cells were then incubated with 
primary antibody cocktails for 30 min at 4°C in the dark (For CACs, Alexa700 anti-
mouse CD45, BD Biosciences, Cat# 560510; BV650 anti-mouse Flk1, BD 
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Biosciences, Cat# 740539; PerCP-eFluor710 anti-mouse CD31, eBioscience, 
Cat# 46-0311-82. For immune cells and monocytes, PerCPCy5.5 anti-mouse NK 
1.1, BD Biosciences, Cat# 551114; BV500 anti-mouse CD3, BD Biosciences, Cat# 
560771; PE/Cy7 anti-mouse CD11c, BD Biosciences, Cat# 558079; PE anti-
mouse Ly6G, BD Biosciences, Cat# 551461; BV421 anti-mouse CD115, 
Biolegend, Cat# 135513; FITC anti-mouse Ly6C, Biolegend, Cat# 128006). After 
washing, the cells were then stained with flexible viability dye eFluor 780 
(eBioscience, San Diego, California, USA) for 30 min at 4°C, washed with PBS 
twice, then fixed with 1% PFA for flow cytometry.  
 
Data analysis and statistics  
 
Data were firstly evaluated for normal distribution using JMP software. For multi-
group comparisons of normally distributed data, one-way or two-way ANOVA was 
performed followed by an appropriate post hoc t test. The nonparametic Kruskal–
Wallis and pairwise Wilcoxon tests were used for microbiota analysis. The data 
sets were considered significantly different if the p value amounted to <0.05. 









No change was observed in the bacterial species richness in fecal 
samples from ACE2KO-Akita mice 
  
After 16S rRNA gene sequencing, alpha diversity was first performed to assess 
species richness and evenness in a cohort of mice. Alpha diversity measures the 
amount of unique bacterial species within each sample (species richness) and the 
abundance distribution of each species (species evenness). In Figure 4-1, alpha 
diversity was performed using different calculation metrics, including observed, 
Chao1, ACE, Shannon, Simpson, InvSimpson, as well as Fisher. It revealed a rich 
bacterial community in all samples, as a range of 125 to 367 unique bacterial 
Operational Taxonomic Units (OTUs >97%) was observed within each sample. 
Interestingly, the wild type group was found to possess the highest average 
observed species richness when compared to the other groups, however the 
difference was not statistically significant. In addition, a consistent pattern of 
difference between Akita and ACE2KO-Akita mice was no observed by alpha 
diversity analysis. 
 




Different from alpha diversity analysis, beta diversity is used to measure the 
phylogenetic distance between the bacterial community in each sample, therefore 
this allows you to evaluate bacterial diversity among samples. In Figure 4-2A, each 
point on the plot is indicative of the entire bacterial community within a sample by 
PLS-DA plot. Samples that are closer together share similar microbial community 
makeups, whereas samples that are further apart are less similar. We observed 
defined clustering of all cohorts. Therefore, taxonomic comparisons were 
generated to identify taxa driving shifts in microbial community structure.  
 
Phylum-level taxonomic assignments of 16S rRNA gene sequences revealed 
general microbial community composition within the 46 samples (Figure 4-2B). 
Slight differences between the cohorts were observed at the phylum taxonomic 
rank. The Firmicutes were observed in greatest abundance across all samples, 
with average relative abundance of 57.6% across all samples. Marginal differences 
in phyla relative abundances were observed between the sample cohorts. 
Therefore, LefSe enrichment tests were calculated to unearth genera significantly 
enriched within each respective cohort. 
 
Bacterial taxa involved in the development of diabetes were particularly 
enriched in ACE2KO-Akita mice 
 
Since defined cluster among genotypes was observed, we then generated LefSe 
plots to display biomarker taxa driving shifts in microbial community structure 
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among different genotypes. In general, a total of 62 significantly enriched taxa 
(p<.01, LDA > 3.0) were identified within all 4 different types of mice, 29 of which 
were found to be enriched within the Akita group, 19 within the ACE2KO, 8 within 
the ACE2-KO Akita mice, and only 6 within the WT group (Figure 4-3A). To better 
understand the effect of ACE2 on bacterial taxa in diabetes, we further compared 
the differences of taxa between Akita and ACE2KO-Akita. Very interestingly, when 
compared to Akita alone group, the most enriched taxa Ruminococcaceae, 
Tenericutes, Mollicutes, as well as Clostridiaceae in ACE2KO-Akita mice were 
found to be involved in the development of diabetes (Figure 4-3B). One study 
showed that Ruminococcaceae and Clostridiaceae were more abundant in bio-
breeding diabetes-prone rats than diabetes-resistant ones [336]. Tenericutes was 
also found to be enriched in STZ-induced type 1 diabetes model [337], while 
Mollicutes enriched in a high fat diet-induced diabetic mouse model [338]. All the 
results suggested that loss of ACE2 worsen diabetes-mediated gut dysbiosis at 9 
months of disease. 
 
Differential functional gene expression profiles were observed among 
different genotypes 
 
As we determined a distinct taxa profile in each genotype, we next were interested 
in identifying the functions of the enriched taxa within each group. 
Metatranscriptome analysis was performed and PLS-DA analysis was conducted 
to compare overall differences in functional gene (Kegg Orthology) expression 
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profiles among different genotypes. Here, we can see defined clustering of 
samples in 3D-space, indicating differential functional gene expression profiles 
among groups (Figure 4-4). This serves as a preliminary indication that diabetes 
and ACE2 deficiency may shape the gene expression profiles of the present 
microbial consortia. A heatmap of counts per million (CPM) normalized counts of 
Metaphlan estimated taxonomic read hits was also generated to visualize 
differences in prominent taxa among different groups (Figure 4-4). Samples are 
clustered based on similarity of active taxa profiles. While clustering of samples is 
observed among cohorts, there is overlap among cohorts as well. This further 
suggests greater differences between the functional expression profiles rather 
than taxonomic composition. 
 
ACE2KO-Akita group had the most defined functional expression profile 
among all 4 genotypes 
 
LefSe plot were generated to display enriched expressed functional gene pathway 
(MetaCyc) within each respective genotype cohort. Figure 4-5 displays all taxa 
found to be significantly (p < 0.05, LDA > 1.0) enriched within each sample cohort. 
The Y-axis displays each respective enriched functional pathway, whereas the X-
axis displays the corresponding LDA enrichment score, which quantifies the 
strength of enrichment within each respective cohort (separated by color). As 
indicated by previous PLS_DA analysis, the Akita-ACE2KO cohort appears to 
have the most defined functional expression profile, as it possesses the highest 
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number (16) of significantly enriched functional pathways when considering all 4 
genotypes. Akita samples were found to possess 3 enriched functional pathways, 
the ACE2KO cohort was found to possess 1 enriched functional pathway, and the 
WT cohort was found to possess 0 enriched functional pathways (Figure 4-5).  
 
We further compared enriched functional pathways between WT and Akita and 
between Akita and ACE2KO-Akita. There were multiple amino acid biosynthesis 
pathways in microbial community functions from WT, Akita as well as ACE2KO-
Akita. The super pathway of aromatic amino acid biosynthesis was enriched in 
Akita mice as compared to WT and can be a possible biomarker for the progression 
of diabetes (Figure 4-6 A). In several clinical studies, the serum levels of aromatic 
amino acid were found to be associated with insulin resistance, obesity and 
development of diabetes [339-342].  It is worth noting that two major functional 
pathways in the gut microbiome in ACE2KO-Akita mice both involved 
peptidoglycan (PGN) biosynthesis when compared to Akita mice (Figure 4-6 B).  
PGN can penetrate from the gut into the blood and even into bone marrow cells 
and levels are reduced in germ-free mice [343]. PGN can systemically mediate the 
innate immune system, augment inflammation and cause profound whole body 
insulin resistance via the pattern recognition receptor Nod1 signaling pathway 
[111, 344-346].  
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ACE2 deficiency mainly affected the infiltration of CACs into the Gut, 
but not the proinflammatory and immune cell types 
 
Impaired gut-vascular barrier and increased permeability in diabetes provide the 
opportunity for the gut microbial antigens to cross the gut barrier and cause 
systemic inflammation. We have previously shown that ACE2 affects bone marrow 
HSPCs function. CACs are derived from HSPC and play an important role in 
vascular repair. Studies showed that bone marrow-derived cells migrate to the gut 
and impact its function. We next evaluated the CAC levels in the four cohorts of 
mice. As assessed by flow cytometry, there was a decrease in the levels of CACs 
(CD45+CD31+Flk1+) in the bone marrow in Akita mice (Figure 4-7B). Loss of ACE2 
led to a more profound reduction of CAC levels compare to the diabetics (Figure 
4-7B). Consistent with this observation, we detected less infiltration of CACs into 
the gut in ACE2KO-Akita mice compare to Akita mice (Figure 4-7C). Interestingly, 
diabetes did not affect the percentages of bone marrow-derived T cells 
(CD45+CD3+NK1.1-), NK cells (CD45+NK1.1+CD3-) or neutrophils (CD45+NK1.1-
CD3-/CD115+Ly6G+) in the small intestine (Figure 4-7E-G). We accessed the 
monocyte population and showed that diabetes neither changes the percentages 
of bone marrow derived Ly6C+ monocytes (CD45+NK1.1-CD3-/Ly6G-
/CD115+CD11b+/Ly6C+) nor Ly6C- monocytes (CD45+NK1.1-CD3-/Ly6G-
/CD115+CD11b+/Ly6C+) in the gut (Figure 4-7H, I). 
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ACE2KO deficiency did not worsen diabetes-mediated impairment of 
gut mesenteric artery flow after ischemia/reperfusion 
 
We observed less infiltration of CACs into the intestine of ACE2KO-Akita mice, 
which plays an essential role in vascular repair. We access whether loss of ACE2 
leads to impaired mesenteric blood flow after ischemia/reperfusion (I/R). We first 
assessed gut blood flow after occluding the mesenteric arteries for 30 minutes 
followed by 1-hour reperfusion. Figure 4-8 shows that even at the baseline levels, 
diabetic mice had reduced blood flow compared to non-diabetic controls. After I/R 
injury, the Akita group only had 20% blood flow recovery compare to their baseline, 
while WT mice had almost 90% recovery of their blood flow. Interestingly, 
ACE2KO-Akita mice reacted similarly as Akita mice both at the baseline and after 
I/R injury. The absence of ACE2 did not further enhance diabetes-induced 




In this study, we demonstrate for the first time that loss of ACE2 expression 
changed the composition and functional gene pathway profile of gut microbiota in 
diabetes. ACE2 deficiency also led to less filtration of bone marrow derived CACs 
into the small intestine. In contrast, we did not observe alterations in bone marrow 
derived immune cell types (T cells and NK cells) or Ly6C+ monocytes.  
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Alterations of gut microbiota in T1D animal models and human subjects have been 
observed in several studies. However, it is still largely unknown the exact 
contribution of gut microbiota to development of diabetes or its complications due 
to multiple reasons, including the environmental effects on the complexity and 
diversity of gut microbes, large variations between individuals studied, and ethnic 
differences in studied populations [100, 327, 330, 347]. Beside the environmental 
effect, how the host precisely affects the gut microbiota and what are the 
underlying molecular mechanisms that modulate microbiota composition are still 
unclear. Despite the difficulties of microbiota study, probiotic treatment and gut 
microbiota modulation, as a therapeutic target, still have tremendous potential for 
treatment of diabetes [348-350]. In our study, we performed 16S rRNA genes 
sequencing using bacterial DNA extracted from fecal samples of Akita and 
ACE2KO-Akita mice at 9 months of diabetes as well as age-matched controls. 
Neither diabetes nor ACE2 deficiency affected species richness of the phylotypes 
among the genotypes. Consistent with reports from other researchers, we also 
observed that the gram-positive Firmicutes and the gram-negative Bacteroidetes 
were the most abundant bacterial phyla in all the fecal samples [351, 352]. In 
addition, there was a slight trend that diabetic Akita mice tend to have more 
Bacteroidetes and less Firmicutes as compared to WT mice, however, was not 
statically significant. We did not observe the same trend in ACE2KO-Akita mice. 
Although it is suggested an increased Bacteroidetes and reduced Firmicutes in 
diabetic human subjects as well as mouse model [97-99], it is difficult to make the 
conclusion that the ratio of Firmicutes/Bacteroidetes is causative in gut dysbiosis. 
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There are mainly 2 reasons: Firstly, there is the inconsistency of the results 
reported by the different research group. While several studies a suggested 
decreased ratio of Firmicutes/Bacteroidetes, other observed no change or 
increased ratio of that in diabetes [101, 353]. Interestingly, in obese subjects, the 
trend of Firmicutes/Bacteroidetes is increased reported by several studies [354, 
355]. Therefore, it is hard to just simply conclude which phylum are more 
beneficial. More importantly, the two dominant bacterial phyla (Bacteroidetes and 
Firmicutes) generally represent two large groups of bacteria and can be subdivided 
into hundreds of genera and thousands of different species [351, 356].  
 
After analysis of general phyla composition in different cohorts, we further 
performed LefSe enrichment tests to further unearth genera significantly enriched 
within each group. At the phylum level, we observed increased Tenericutes and 
decreased Proteobacteria. Consistent with our data, previous studies also have 
showed that Tenericutes is more abundant in both STZ-induced type 1 diabetes 
model as well as type 2 diabetic db/db mice [337, 357], and Proteobacteria less 
abundant in type 2 diabetic subjects [353]. At the level of class, Mollicutes was 
increased in ACE2KO-Akita mice, which was also reported to be more abundant 
in high fat diet-induced diabetes [338]. At the level of order, RF39 was found to be 
enriched in ACE2KO-Akita mice as compared Akita alone. Annalouise et al found 
that RF39 is positively correlated with plasma trimethylamine N-oxide (TMAO) 
level, which, as a risk marker of cardiovascular dysfunction, is elevated in diabetes 
[358, 359]. At a family level, ACE2KO-Akita mice showed a more robust increase 
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in Clostridiaceae, Ruminococcaceae, and decrease in Bacteroidales S24-7 and 
Bacteroidaceae levels when compared to Akita. Supported by the previous study, 
both Clostridiaceae and Ruminococcaceae were reported to be more enriched in 
bio-breeding diabetes-prone rats than diabetes-resistant ones [336]. Decreased 
Bacteroidales S24-7 was also reported nonobese type 1 diabetic (NOD) mice, 
which may protect NOD from developing diabetes through alterations in Treg cells, 
CD11b+ dendritic cells, and IFN-γ levels [360]. The role of Bacteroidaceae in 
diabetes development is still controversial. Bacteroidaceae was more abundant in 
young children with T1DM associated autoimmune defect [97]. However, in 
another study, when compared to women with gestational diabetes, 
normoglycemic women are restricted to the population with a Bacteroidaceae-rich 
microbiome [361]. At the level of genus, an increased Ruminococcus and 
decreased Blautia and Bacteroides were observed in ACE2KO-Akita. The 
previous study also showed increased Ruminococcus in NOD type 1 diabetic mice, 
which promote pathogenesis by modulation of immune cell types [360]. Enriched 
Blautia is associated with increased plasma glycerol level and branch-chain amino 
acids, and may associate with the development of obesity. Bacteroides is largely 
reduced in T2DM patients when compared to pre-diabetes and non-diabetes 
subjects, and may be negatively associated with glucose intolerance [362]. Taken 
together, ACE2KO-Akita mice fecal samples are more enriched with the bacteria 
involving in the development and pathogenesis of diabetes and less abundant with 
those in favor of protection.  
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Besides the alterations of microbial composition, it is more important to gain insight 
into how the microbiota changes affect their functions and interacts with the host. 
Metatranscriptomics analysis will allow us to examine the genes that are 
expressed and have active functions in the complex bacterial communities, 
therefore provides the information of functional alterations of microbiota that shape 
the gut microbiome toward a disease-driving configuration. LefSe plot of 
metatransciptome analysis revealed that ACE2KO-Akita has the most enrich 
functional gene pathways among all the 4 cohorts. Interesting, when compared to 
Akita mice, ACE2KO-Akita mice are particularly enriched with the biosynthesis 
pathways of PGN. Gut microbiota-derived PGN can penetrate into circulation, 
augment systemic inflammation and initiate systemic innate immune responses 
[343]. Studies showed that PGN induces IL-6 and TLR-2 expression, and trigger 
inflammation in adipocyte [363]. PGN can also induce insulin resistance during a 
high fat diet [106]. All these suggesting an important role of PGN in the 
pathogenesis of diabetes. It is also worth noting that there are lots of amino acid 
biosynthesis pathways that are active and enriched in ACE2KO-Akita mice, 
including L_lysine, L_histidine and L_proline biosynthesis. Previous study showed 
that ACE2 deficiency led to amino acid malnutrition and disturbed microbial 
ecology the gut [161]. Therefore, the increased amino acid biosynthesis pathways 
may possibly due to a compensation response of gut microbiota.  
 
In sum, we showed for the first time the ACE2 deficiency contribute to the changes 
of gut microbiota in the context of diabetes. Loss of ACE2 shaped the complex 
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microbial community toward a pathogenesis configuration with enriched bacteria 

















Figure 4-1. A consistent pattern of alpha diversity rarefaction curves among 
cohorts. No differences in bacterial species richness and evenness were observed 
in Akita mice and ACE2KO-Akita mice as compared to non-diabetic groups (n = 9-
17). Abbreviations: WT, wild type; ACE2KO, ACE2 knockout (ACE2-/Y); ACE2KO-

























Figure 4-2. Distinct clustering of samples from the four cohorts of mice by beta 
diversity analysis. A: 2D PLS-DA analysis was performed to compare the overall 
bacterial community phylogenetic differences (n = 9-17). B. relative abundance 





























all samples (n = 9-17). The Firmicutes and Bacteroidetes were found dominating 
microbial community composition within all samples. Abbreviations: WT, wild type; 
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Figure 4-3. Significantly enriched taxa within each genotype. A: 62 enriched taxa 
found to be significantly (p <.05, LDA > 3.0) enriched within each respective 
sample cohort. The Y-axis displays each respective enriched taxa, whereas the X-
axis displays the LDA score, which quantifies the strength of enrichment within 
each respective cohort (separated by color). Multiple enriched taxa of similar 
phylogeny can be observed within each respective cohort (n = 9-17). B: 10 
enriched taxa found to be significantly enriched in ACE2KO-Akita mice as 
compared to Akita mice (separated by color), with a lot of them involved in diabetes 
development (highlighted by red text box) (n = 9-17). Abbreviations: WT, wild type; 






Heatmap of counts of Metaphlan
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Figure 4-4. Distinct functional gene profile in the bacterial community by 
metatranscriptome analysis.  Left panel： PLS-DA analysis was conducted to 
compare overall differences in functional gene (Kegg Orthology) expression 
profiles between genotypes. Defined clustering of samples in 3D-space indicated 
differential functional gene expression profiles between genotype cohorts. Right 
panel: A heatmap of CPM normalized counts of Metaphlan displayed differential 
abundances of several prominent taxa, and observe similarities in the microbiome 
between samples of similar genotypes. n = 4 per group. Abbreviations: WT, wild 













Figure 4-5. ACE2KO-Akita mice displayed the most enriched functional gene 
pathways in fecal samples by LefSe plots. All pathways found to be significantly (p 
<.05, LDA > 1.0) enriched were shown on the graph. The Y-axis displays enriched 
functional pathway in each genetype, whereas the X-axis displays the 
corresponding LDA enrichment score (separated by color). n = 4 per group. 
Abbreviations: WT, wild type; ACE2KO, ACE2 knockout (ACE2-/Y); ACE2KO-Akt, 
ACE2 knockout-Akita (ACE2-/YIns2WT/C96Y). 
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Figure 4-6. Increased functional pathways of peptidoglycan biosynthesis in 
ACE2KO-Akita mice compared to Akita mice by LefSe plots. All pathways found 
to be significantly (p <.05, LDA > 1.0) enriched were showed on the graph (red text 
box, beneficial pathways in diabetes development; red text box, detrimental 
pathways in diabetes development). A: comparison between WT and Akita; B: 
comparison between Akita and ACE2KO-Akita. The Y-axis displays enriched 
functional pathway in each genetype, whereas the X-axis displays the 
corresponding LDA enrichment score (separated by color). n = 4 per group. 
Abbreviations: WT, wild type; ACE2KO, ACE2 knockout (ACE2-/Y); ACE2KO-Akt, 
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Figure 4-7. Loss of ACE2 worsens diabetes-induced less infiltration of bone 
marrow-derived CACs into the small intestine. A: Representative flow gating 
schema of CAC population of each group using small intestine lamina propria cells 
(LP) (Gates: CD45+). B-C: Quantitative data of percentage of CACs 
(CD45+CD31+Flk-1+) showed that ACE2KO-Akita had the least percentage of 
CACs in bone marrow (B) as well as in the small intestine (C) (Bone marrow 
samples: n = 13-18 per group; LP sampels: n = 8-14 per group). D: Representative 
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differences of phenotypic T cells (E), NK cells (F), neutrophils (G), Ly6C+ 
monocytes (H) and Ly6C- monocyte (I) in the small intestine LP layer among the 4 
different cohorts (n=9-14). Abbreviations: CAC, circulating angiogenic cells; NK 
cell, natural killer cell; LP, lamina propria; WT, wild type; ACE2KO, ACE2 knockout 
















Figure 4-8. ACE2 depletion did not worsen diabetes-induced impairment of 
mesenteric blood flow after ischemia/reperfusion. Upper panel: Representative 
images of Laser Doppler blood flow of mesenteric arteries at a baseline level and 
at 1-hour perfusion after 30 minutes ischemia. Lower panel: quantitative data of 
baseline blood flow levels before ischemia/reperfusion showed that Akita groups 
had reduced gut blood flow as compared to their non-diabetic controls. The right 
graph showed blood flow levels after 30 minutes ischemia followed by 1 hour 
reperfusion. Both Akita and ACE2KO-Akita showed reduced blood flow recovery 
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Chapter 5: Conclusions and future studies 
 
In this study, ACE2KO-Akita mice were generated and carefully examined to better 
understand the role of the protective RAS axis in maintaining bone marrow 
function, the retina and the gut microbial ecology. As shown in Chapter 2, Akita 
mice did not change their number of total LSK cells. However, when LSK cell were 
subdivided into LT-HSC and ST-HSC using CD135 and CD34 phenotypic markers, 
a reduction of LT-HSCs was observed as well as a tendency towards a decrease 
of ST-HSCs. Loss of ACE2 expression worsened the diabetes-induced bone 
marrow defects as a further reduction in the numbers of the ST-HSCs and LT-
HSCs was observed.  
 
Migration and proliferation functions of HSPCs are important properties reflecting 
their vascular repair potential. These cells need to sense the chemoattractants 
released from the injury site and migrate toward the injured area. The cells need 
to expand and secrete paracrine factors to supported the impaired vasculature.  
Impaired migration and proliferation function of HSPCs was observed in Akita 
mice. ACE2 deficiency exacerbated the diabetes-mediated impairment of HSPC 
functions. It is worth noting that when the cells were treated with either Ang-(1-7) 
or alamandine, the migration and proliferation functions were restored in ACE2KO-
Akita mice even at the 9 months of diabetes timepoint. ACE2 deficiency not only 
caused HSC depletion and impaired functions of HSPC, but also affect the balance 
of hematopoiesis.  
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By the CFU assay, bone marrow cells isolated from Akita mice formed a higher 
number of CFU-G/M/GM than those from WT mice. Loss of ACE2 further 
exacerbated this change. In turn, there was less common lymphoid progenitors in 
the diabetic bone marrow detected by flow cytometry analysis. ACE2 deficiency 
worsen the pathological alteration in diabetes, suggesting its important role in 
maintaining the balance of myelopoiesis and lymphopoiesis. All these results 
suggest that the protective RAS axis (ACE2/Ang-(1-7)/Alamadine) is important in 
shaping the phenotype of diabetic bone marrow and may be a promising target for 
restoring of bone marrow HSPC function and for vascular repair.  
 
In the investigation of the retinal defect caused by ACE2 depletion (Chapter 3), the 
same cohorts of mice were used. Interestingly, bone marrow changes observed in 
Chapter 2 were accompanied by a greater number of acellular capillaries in the 
retina of ACE2KO-Akita mice compared to the Akita mice. Acellular capillaries are 
considered the “gold standard” for DR and are caused by endothelial cell and 
pericyte loss. In addition, only the ACE2KO-Akita group exhibited persistent 
reduction in scotopic a- and b-waves over the duration of diabetes.  
 
Human subjects with different stages of DR were recruited and defects in CD34+ 
cells were identified in subjects with retinopathy. Diabetic subjects with no 
complication exhibited increased levels of plasma Ang-(1-7) as well as MAS 
receptor gene expression in CD34+ cells compared to healthy controls, suggesting 
a compensatory response in early stages of diabetes. However, the plasma Ang-
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(1-7) level and CD34+ cell MAS expression was dramatically reduced with the 
development of NPDR.  Reduced MAS receptor gene expression in CD34+ cells 
was accompanied by the impaired migratory function of the cells isolated from 
subjects with NPDR. The reduced migratory function was corrected by the 
exogenous supplementation of Ang1-7 and alamandine. Collectively, the results 
suggest more advanced DR in Akita mice with ACE2 deficiency. Our human data 
provided further support that the deficiency of the protective RAS within HSPC may 
be associated with the progression of DR. 
 
Chapter 4 focused on the investigation of gut microbial dysbiosis in Akita and 
ACE2KO-Akita mice. 16S rRNA were isolated from fecal samples of a group of 
mice and gene sequencing was performed to access the gut microbiota changes 
in the mice. In general, both Akita and ACE2KO-Akita mice showed similar bacteria 
species richness as their non-diabetic controls. A difference of diversity in microbial 
community was observed among different genotypes by beta diversity analysis 
and the enriched taxa that contribute to the diversity differences were identified. 
Fecal samples from ACE2KO-Akita were enriched with a great diversity of bacterial 
types that were all reported to contribute to diabetic pathogenesis, including 
Tenericutes at the phylum level, Mollicutes at the class level, RF39 at the order 
level, Ruminococcaceae and Clostridiaceae at the family level, and Ruminococcus 
at the genus level.  
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Metatranscriptomic analysis revealed that genes involved in PGN biosynthesis 
pathways and in amino acid biosynthesis were actively expressed in ACE2KO-
Akita mice as compared to Akita mice. PGN is considered as a trigger for chronic 
inflammation. Interestingly, loss of ACE2 resulted in less infiltration of CACs into 
the LP in small intestine, without affecting bone marrow-derived T cell, NK cells 
and monocytes. All these results suggested that loss of ACE2 resulted in an 
alteration of microbiota composition as well as gene signaling pathways. Thus, the 
RAS may be a potential therapeutic target for diabetes-induced gut dysbiosis.  
 
The 3 studies described in Chapters 2, 3 and 4 may on first glance appear 
disparate; however, they are interconnected. Bone marrow cells influence vascular 
repair, blood flow and endothelial barrier integrity by paracrine mechanisms and 
contribute to the pathological changes in diabetic microvascular complications 
[26].  
 
An extensive literature supports that in chronic diabetes bone marrow cells 
become dysfunctional and are unable to support the function of the vasculature or 
repair injured tissue [219, 220, 225, 364-368]. CACs while representing a small 
percentage of circulating cells have a robust vascular protective effect largely 
mediated by their production of growth factors and cytokines [26]. These factors 
are vasomodulatory and can mediate changes in vascular reactivity as well as 
maintain the barrier characteristics of the endothelium [369]; however, CACs such 
as CD34+ cells of diabetics typically loose this ability and secrete proinflammatory 
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and vasoconstrictive factors [26, 38]. Additionally, diabetic CACs lose their ability 
to migrate into tissues to respond to local injury [221, 225, 370, 371].  
 
Levels of ACE2 mRNA in CD34+ cells isolated from peripheral blood of diabetic 
individuals predicted the in vitro function of these cells and directly correlated with 
the severity of retinopathy. ACE2 generates Ang-(1-7) and thus Ang-(1-7) 
mediates the beneficial effect of ACE2. Ang-(1-7) is dependent on MAS receptor 
expression. Ang-(1-7) can enhance the migratory function of CACs in vitro [93]. 
Ang-(1-7) overexpression of lentiviral gene modification restored in vitro 
vasoreparative function of diabetic CD34+ cells and “in vivo” homing efficiency to 
areas of ischemia [93]. Genetic ablation of MAS prevented ischemia-induced 
mobilization of bone marrow cells and impairs blood flow recovery [281, 372]. In 
the current study, the peptide alamandine beneficially impacted the migration of 
dysfunctional CD34+ from diabetics with retinopathy.  
 
Thus, these studies and others suggest that activation of the ACE2/Ang1-7/MAS 
pathway stimulates the function of dysfunctional murine and human BM cells in 
diabetes [373]. The impact of the RAS on DR finds support in numerous studies 
including that all classic RAS components [prorenin, renin, angiotensinogen, 
angiotensin-converting enzyme (ACE)-1, angiotensin II (Ang II), and the Ang II type 
1 receptor (AGTR1)] are significantly elevated in ocular tissues of diabetic patients 
[374, 375] and animals [216, 376].  
 
 121 
Lack of sufficient penetration of these agents across the blood-retinal barrier was 
deemed responsible for why suppression of the classic RAS failed to treat 
advanced DR [216]. These studies led to the notion that restoring the balance 
between the classic RAS and the vasoprotective RAS within HSPCs represented 
a viable strategy for controlling DR in humans. Strategies focused on restoring the 
local retinal RAS balance by bolstering the vasoprotective RAS which results in 
diminished oxidative stress and chemokine production, decreased inflammatory 
cell infiltration and prevention of retinal vasodegeneration, the key histologic 
characteristic of DR. Previously, we showed that DR can be prevented/reversed 
by increasing retinal ACE2 using adenoassociated virus (AAV)-ACE2 [215, 216]. 
 
However, in order to further confirm a more important role of RAS within bone 
marrow HSPC over the systemic RAS, more studies should be performed. Firstly, 
we showed that loss of ACE2 led to reduced phenotypic ST- and LT-HSCs in mice 
at 9 months of diabetes and LK cells from ACE2KO-Akita mice showed reduced 
migration and proliferation functions when compared cells from Akita mice. 
However, the blood reconstitution and engraftment functions of HSCs from 
ACE2KO-Akita mice in vivo were not tested under either nondiabetic or diabetic 
conditions. A competitive bone marrow transplantation can be performed to 
address this question.  
 
To perform these studies, donor bone marrow cells should contain 50% HSCs from 
ACE2KO mice (CD45.2) and 50% HSCs from WT mice (CD45.1) and recipients 
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would be Akita and WT mice (CD45.1) at 2 months of age. After lethal irradiation, 
the mixed donor HSCs should be transplanted into recipients. Four months later, 
blood mononuclear cells would be stained with anti-CD45.1 and anti-CD45.2 
antibodies and the proportion of these two types of blood cells analyzed by flow 
cytometry.  
 
If diabetic microenvironment plays an essential role in HSC hematopoiesis 
irrespective of ACE2 loss, the Akita recipients in general should have lower 
engraftment rate compared to WT recipients. If ACE2 deficiency caused impaired 
reconstitution function of HSCs, the percentage of CD45.2 mononuclear cells 
should be much less than CD45.1 ones in both WT and Akita recipients.  
 
Another important question to address is that whether loss of ACE2 in the bone 
marrow is the causative for the advancement of DR.  Even though, we have 
already observed that loss of ACE2-mediated bone marrow defects is associated 
with more advanced retinopathy, we still would have to perform a bone marrow 
transplantation to further confirm these observations.  Either WT bone marrow or 
ACE2KO bone marrow should be transplanted into lethal irradiated WT and Akita 
recipients. If bone marrow ACE2 deficiency leads to diabetic retinopathy, we 
should observe that Akita mice transplanted with ACE2KO bone marrow should 
have more advanced DR than Akita mice with WT bone marrow.  
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Another important experiment to perform to address the same question is 
generating a bone marrow-specific ACE2 overexpressing diabetic mouse model. 
We have already successfully established a hACE2 knock-in (ACE2KI) mouse 
model with a EF1α-LoxP-Stop-LoxP cassette in front of hACE2 cDNA sequences. 
We are planning to breed the ACE2KI mice with vav-1 Cre mice to generate the 
bone marrow-specific ACE2KI mice, which will be then bred with Akita mice. In our 
hypothesis, the bone marrow ACE2KI-Akita mice should exhibit less bone marrow 
defects and be protected from development of DR when compared to the Akita 
mice. However, there is one limitation of the experiment, as currently none of the 
vav-1 Cre mice commercially available are inducible, therefore, we cannot control 
precisely when the ACE2 gene expression occurs. With the current experimental 
paradigm, ACE2 would be overexpressed in the bone marrow from birth on and 
could potentially impact bone marrow development and hematopoiesis.  
 
Another connection we observed is the bone marrow and gut microbiota studies. 
In the case of T1D, an alteration of the intestinal microbiota, changes in intestinal 
immune responses and increased gut permeability all together form a “perfect 
storm” for the progression of diabetes [377]. Neu et al. showed that there was an 
increased permeability of gut epithelial barrier with low expression of tight junction 
molecules, including claudin, even before the onset of T1D in bio-breeding 
diabetes-prone rats  [378]. Not only in rodent models, abnormal intestinal 
permeability was also observed in T1D by multiple clinical studies [379-383].  
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Besides the epithelial barrier, recently, Spadoni et al. verified the existence of gut 
vascular barrier and demonstrated that the gut vascular barrier may even play a 
more important role in protecting the interior of the host body from pathogenic 
bacteria and the aberrant luminal microbial antigens [267]. To the best of our 
knowledge, no one has examined the gut vascular permeability in diabetes yet. 
 
In Chapter 4, we observed that ACE2 deficiency resulted in diabetes-mediated 
depletion of bone marrow-derived CACs in the gut lamina propria. Bone marrow 
cells are present in and affect a variety of other organs, including liver, spleen and 
gut. Therefore, it is also important to assess the numbers of bone marrow-derived 
CACs in liver and spleen tissues. This can help us to verify that whether ACE2 
deficiency-mediated less infiltration of CACs is a gut tissue specific event or is also 
happening in other organs.  
 
CACs are known to play an important role in vascular repair.  Interestingly, when 
we checked the gut blood flow of these mice, we only observed that diabetic groups 
had reduced basal mesenteric blood flow levels, and reduced blood flow recovery 
after 30 minutes of ischemia followed by 1 hour perfusion. However, loss of ACE2 
did not further worsen diabetes-mediated decrease in mesenteric blood flow 
recovery.  
 
There are two possible explanations for the results of mesenteric blood flow study: 
firstly, it may just simply due to a short observation time of reperfusion (1 hour) 
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after ischemia, so that the reparative mechanisms of CACs have not been initiated, 
or the time is too short to show the vaso-reparative benefits. The other possible 
reasons may be that ACE2 is more important for maintaining the microvasculature 
than the macrovasculature. In the chapter 3, we did not observe deleterious effects 
of ACE2 deficiency on macrovasculature, as ACE2KO-Akita mice exhibited normal 
mean blood pressure and the impaired endothelial dysfunction of aorta rings, 
similar to the Akita alone. In contrast, we demonstrated increased acellular 
capillaries in retinal microvasculature isolated from ACE2KO-Akita mice when 
compared to Akita mice. Therefore, small vessel density in the small intestine 
needs to be evaluated in ACE2KO-Akita mice to address this question. We have 
stained the small intestine for CD31 antibody and are currently quantifying the 
density differences using Aperio software. 
 
More importantly, it is definitely critical in future studies to assess the vascular 
permeability of the gut in each of the cohorts of mice to test the hypothesis that 
ACE2KO deficiency worsens diabetes-induced increases in gut endothelial 
permeability. In order to examine this, we propose to inject 70KDa FITC-Dextran 
intravenously.  Ten minutes following injection of the FITC dextran, mice will be 
euthanized and the small intestine samples will be examined under the 
microscope.  Fluorescence outside of the blood vessels will be quantified to show 
the extent of leakage. Peritoneal fluid will be collected as an alternative way to 
quantify fluorescence intensity. Eyes will also be collected and examined to 
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confirm that the increases in gut permeability occur simultaneously with increases 
in retinal permeability.   
 
We also plan to measure gut epithelial permeability. To accomplish these studies, 
mice will undergo oral gavage with 40kDa FITC-dextran after 6 hours of fasting. 
Four hours later, blood will be collected under isoflurane anesthesia via cardiac 
puncture right before euthanizing. Blood plasma will be isolated and analyzed for 
FITC fluorescence. Data will be analyzed using a standard curve of FITC-dextran 
dilution. Examining the expression of the tight junction molecules, including ZO-1, 
claudin and occludin by immunohistochemistry would also provide insight into the 
integrity of the endothelium and epithelium. The underlying mechanisms of the 
“leaky gut” may involve the alteration of microbial antigen and increase in 
inflammatory mediators, which upregulate zonulin expression and downregulates 
tight junction proteins, ZO-1 and occludin [113, 384, 385]. Plasma lemma vesicle-
associated protein-1 (PV-1) will be stained on paraffin-embedded sections. PV-1, 
as a marker of endothelial permeability, normally is not expressed in the LP, but 
can be induced by pathogenic bacteria [267, 386, 387].  
 
In our hypothesis, Akita mice should have increased gut endothelial and epithelial 
permeability, with reduced expression of tight junction and adherent junction 
molecules when compared to WT mice. PV-1 expression should also be activated 
in the LP of the diabetic gut. ACE2 ablation should further worsen those 
pathological changes. 
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In our study, we observed reduced CACs in the diabetic bone marrow as well as 
in the LP of the small intestine. In addition, loss of ACE2 worsen the changes as 
the least infiltration of bone marrow-derived CACs into the small intestine in 
ACE2KO-Akita mice when compared to age-matched controls. This is particularly 
interesting because CACs play an essential role in vascular repair [221, 225, 370, 
371]. Gut endothelial integrity plays an important role in preventing intestinal 
microbes from accessing the bloodstream and distal organs in mice [267]. We 
raised the question that whether ACE2KO-mediated loss of bone marrow-derived 
CACs contribute to the pathogenesis of the increase in gut vascular permeability 
observed in diabetic mice. To address this question, we are planning to isolate 
CACs from WT bone marrow and treat the Akita and ACE2KO-Akita mice with 
those “normal” CACs via intraperitoneal injection for up to 7 days. Then, access 
whether CAC administration can help to restore the gut vascular integrity and 
increase expression of tight junction and adherent junction molecules, as well as 
decrease the expression of PV-1 in LP in ACE2KO-Akita mice. 
 
It is interesting that we observed ACE2KO-Akita mice had an alteration of gut 
microbiota composition, with a robust increase of the types of bacteria that involved 
in the development of diabetes. However, it is still unknown what is the underlying 
mechanisms that cause the modulation of gut microbiota. Because we used a 
global ACE2KO mice model in our study, it is difficult to verify that whether the 
changes in the gut microbiota are due to the bone marrow defects or the deficiency 
of ACE2 in the gut itself. One way to test the importance of intestinal ACE2 in 
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diabetes-induced microbiota modulation is to establish an intestinal specific 
ACE2KI model, to see if the overexpression of ACE2 in the intestine of Akita mice 
is able to shift the diabetic microbiota composition toward WT enterotype. To test 
the contribution of bone marrow cells in the change of gut microbiota, bone marrow 
transplantation should be performed. Bone marrow cells from ACE2KO mice or 
WT mice should be transplanted in the WT and Akita recipients after lethal 
irradiation. If the Akita mice with ACE2KO bone marrow exhibited a more 
deleterious enterotype when compared to Akita mice with WT bone marrow, it 
suggests that the bone marrow cells at least partially contribute to the change of 
the gut microbiota in diabetes. 
 
Not only an alteration of gut microbiota composition but also a change of functional 
gene expression profile was observed in fecal samples from ACE2KO-Akita mice. 
Loss of ACE2 resulted in activation of genes that are involved in PGN biosynthesis 
in diabetes. PGN is an essential component of the bacterial cell wall and is well 
known as a stimulus for inflammatory responses [388]. Studies showed that PGN 
promoted high-fat diet-induced insulin resistance [106, 111]. Increased gut 
permeability in the diabetic gut may provide an opportunity for increased antigens, 
like PGN, to cross the gut barrier into the circulation. Circulating pathogen-
associated molecules, such as PGN and LPS, lead to low-grade endotoxemia and 
may even affect distal organs, like an eye, through TLRs and NOD signaling 
pathways [268].  
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Thus, another important experiment is to assess the PGN levels in both systemic 
circulation and eye samples in the cohort of mice. In our hypothesis, Akita mice 
should have increased levels of PGN in the plasma and eye samples, while the 
loss of ACE2 caused a further increase in PGN in diabetic plasma and eyes. More 
importantly, we are going to test whether bone marrow-derived CAC administration 
by protecting the gut vascular barrier will result in a reduction in PGN levels in both 
the circulation and in the eye. This will allow us to determine whether the cell-
mediated protection of gut barrier is sufficient to prevent the translocation of 
pathogen-associated molecules. 
 
To further establish a causative connection between the microbial antigen, PGN, 
and DR, WT and Akita mice at 6 months of diabetes can be treated with PGN for 
14 days by intravitreal injection. OCT, ERG, fluorescein angiography and acellular 
capillaries enumeration will be performed to assess whether PGN can initiate the 
same retinal changes in WT mice as are seen in DR and if PGN can worsen 
retinopathy in the diabetic mice.  If the Akita mice administrated with PGN shows 
more advanced retinopathy than the Akita mice injected with vehicle, it suggests 
that PGN plays an essential role in the pathological changes in DR. 
 
In conclusion, we found that the loss of ACE 2 worsened the diabetes-induced 
bone marrow changes and DR. Of note, the phenotypic changes observed in the 
bone marrow-derived cells of ACE2KO-Akita mice, found in diabetic human 
subjects with diabetic retinopathy and could be corrected by RAS peptides, Ang1-
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7, and alamandine. Loss of ACE2 also caused less infiltration of bone marrow-
derived CACs into the gut and an alteration of intestinal microbiota composition 
and cell signaling pathways. An increase in bacteria involved in the development 
of diabetes and active gene expressions in PGN biosynthesis pathway were 
observed.  
 
More importantly, there is definitely more work to be done in order to understand 
the integrative physiology and complexity of how all the systems interconnect with 
each other and work together to contribute to the pathology events in diabetes and 
its microvascular complications. Our study and future experiments will provide 
insight into the therapeutic targets for diabetes and its microvascular 
complications. Hopefully, enhancing ACE2 or Ang 1-7 or alamandine could 
represent a potential therapeutic option for microvascular complications such as 
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